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Summary 
Angina is pain or constricting discomfort that typically occurs at the 
front of the chest and may radiate to neck, shoulders, jaw or arms and 
is precipitated by physical exertion or emotional stress which increases 
myocardial demand. Allopurinol has been shown to prolong the time to 
ST depression on ETT, which is a marker of ischaemia. This may be via a 
number of mechanisms including effect on oxidative stress and 
endothelial stability.  
This three arm cross over, double blind study was designed to establish 
the time of onset of effect of allopurinol and the optimal dose. The 
primary outcome was time to ST depression. Secondary outcomes were 
total exercise time and effect on troponin, oxidised LDL, CRP and BNP 
levels. 
There were 26 participants with a mean age of 70.1 and 77% male. 5 
participants did not complete the study.  
Due to challenges of recruitment this study was underpowered but it 
did appear at 24 hours post study drug administration there was an 
impact on both time to ST depression and total exercise time in the 
active arms of the trial. Furthermore it was shown total exercise time 
improved irrespective of whether the participant was in an active or 
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placebo arm. This may suggest the protocol was contaminated by the 
training effect of repeated high intensity exercise.  
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1 Introduction 
1.1 Angina 
1.1.1 Definition of angina 
Angina is pain or constricting discomfort that typically occurs at the 
front of the chest and may radiate to neck, shoulders, jaw or arms and 
is precipitated by physical exertion or emotional stress which increases 
myocardial demand.1-4 Classic stable angina is predictable in onset, 
reproducible and relieved by rest or glycerol trinitrate (GTN).   Angina is 
the main symptom of myocardial ischaemia and is usually caused by 
atherosclerotic obstructive coronary artery disease (CAD) restricting 
blood flow and therefore oxygen delivery to the heart.  
Angina can be graded by severity on the Canadian Cardiovascular 
Society (CCS) class scale:2 
Class I Ordinary activity such as walking or climbing stairs does 
not precipitate angina 
Class II Angina precipitated by emotion, cold weather or meals 
and by walking upstairs 
Class III Marked limitations of ordinary physical activity 
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Class IV  Inability to carry out any physical activity without 
discomfort – anginal symptoms may be present at rest. 
The likelihood of diagnosis of angina increases with the number of 
cardiovascular risk factors present. These include smoking, 
hypertension, diabetes, family history (first degree relative aged < 65 
years), and hypercholesterolemia. 
1.1.2 Epidemiology 
The Health Survey for England (2006) reported around 8% of men and 
3% of women between 55 and 64 years currently have or have had 
angina.1 The figures for men and women aged between 65 and 74 years 
are around 14% and 8% respectively .1 The Scottish Health Survey 
(2003) reported similar prevalence with 5.1% and 6.7% in males aged 
55-64 and 65-74 respectively. For the same age groups in woman the 
rates were 4% and 6.8%.2  
1.1.3 Diagnosis of angina 
A baseline 12 lead electrocardiograph (ECG) should be performed in 
every patient suspected of having angina. The majority of patients will 
then undergo an exercise tolerance test (ETT). The sensitivity and 
specificity of this test depends on the cohort of patients studied. 
Sensitivity is higher in patients with triple vessel disease and lower in 
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those with single vessel disease. 3, 5 The true diagnostic value of ETT lies 
in its relatively high sensitivity but it is only moderately specific for 
diagnosis of CAD in women.3, 6 
Myocardial perfusion scintigraphy (MPS) with exercise or 
pharmacological stress is an alternative accurate and non-invasive 
investigation which can predict the presence of CAD. It has a useful role 
in those patients unable to exercise adequately on ETT or with ECG 
abnormalities which make ETTs difficult to interpret. It is also useful in 
females  who may have low risk of underlying CAD but a high risk  of 
falsely positive ETT and in patients in whom identification of regional 
ischaemia would be of value (i.e. prior to percutaneous coronary 
intervention( PCI)) 
Coronary angiography is the benchmark investigation for establishing 
nature, anatomy and severity of CAD.  In patients with stable angina it 
should only be considered if patients are identified as high risk or if 
diagnostic uncertainty remains.2 
NICE have issued guidelines on the approach to investigating patients 
presenting with stable chest pain based on the likelihood they will have 
CAD  and advise ‘if people have features of typical angina based on 
clinical assessment and their estimated likelihood of CAD is greater 
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than 90% (see table 1), further diagnostic investigation is unnecessary. 
Manage as angina’.7  
 Non-anginal chest 
pain 
Atypical angina Typical Angina 
 Men Women  Men Women  Men Women 
Age 
in 
years 
Lo Hi Lo Hi  Lo Hi Lo Hi  Lo Hi Lo Hi 
35 3 35 1 19  8 59 2 39  30 88 10 78 
45 9 47 2 22  21 70 5 43  51 92 20 79 
55 23 59 4 25  45 79 10 47  80 95 38 82 
65 49 69 9 29  71 86 20 51  93 97 56 84 
Table 1 Percentage of people estimated to have coronary artery disease according 
to typicality of symptoms, age, sex and risk factors7 
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1.1.4 Standard treatment of angina 
Patients with stable angina should be prescribed a short acting nitrate 
and advised to use this prior to activities which provoke their angina.1 
Beta-blockers should be given as first line anti-anginal therapy and if 
patients cannot tolerate beta-blockers, consider calcium channel 
blockers.  If symptoms remains poorly controlled consider a 
combination of both.  For patients on beta-blocker or calcium channel 
blocker monotherapy whose symptoms are not controlled and who are 
intolerant of the other consider adding a long-acting nitrate, ivabridine, 
nicorandil or ranolazine.  If patients cannot tolerate either beta-blocker 
or calcium channel blockers one of these can be given as monotherapy. 
In addition aspirin, angiotensin converting enzyme (ACE) inhibitor, 
statin and treatment of elevated blood pressure should be given as 
secondary prevention. 
Patients with poorly controlled symptoms despite optimal medical 
therapy should be considered for revascularisation with either PCI or 
coronary artery bypass graft (CABG). 
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1.1.5 Pathophysiology of angina 
Myocardial ischaemia is due to an imbalance between myocardial 
oxygen supply and myocardial oxygen consumption (See figure 1).  
Myocardial oxygen supply is determined by arterial oxygen saturation 
and myocardial oxygen extraction which are relatively fixed under 
normal circumstances and coronary flow which is dependent on the 
luminal cross sectional area of the coronary artery and coronary arterial 
tone.  Coronary flow is also influenced by collateral blood flow, 
perfusion pressure which is determined by pressure gradients from the 
aorta to the coronary artery and, since flow is from epicardium to 
endocardium, from the coronary artery to the endocardial capillaries. 
The flow within the endocardium is determined by the left ventricle 
end diastolic pressure.  In addition coronary flow is affected by heart 
rate which affects the duration of diastole; importantly coronary flow 
occurs primarily during diastole.8 
Myocardial demand is determined by four major factors namely heart 
rate, systolic blood pressure, myocardial wall tension and myocardial 
contractility. 
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Figure 1 Diagram of components of myocardial supply and demand 
 
The luminal cross sectional area of coronary arteries and the coronary 
arterial tone may be dramatically altered by the presence of 
atherosclerotic plaque in the vessel wall resulting in an imbalance of 
oxygen supply and demand when oxygen demand increases such as 
during exertion. The increase in demand is due to an increase in heart 
rate, myocardial contractility and wall stress.3 Ischaemia induced 
sympathetic activation can further increase the severity of ischaemia 
through a variety of mechanisms which can result in further increase of 
myocardial oxygen consumption and coronary vasoconstriction. The 
term ischaemic cascade describes a sequence of events beginning with 
an imbalance between oxygen supply and demand, resulting in 
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metabolic abnormalities, perfusion mismatch and global diastolic and 
systolic dysfunction, ECG changes and often angina.3 9  
In the majority of patients, the pathological substrate of stable angina is 
atheromatous narrowing of the coronary arteries. The normal vascular 
bed has the capacity to reduce resistance, allowing coronary flow to 
increase 5-6 fold during maximal exercise. Reduction in the luminal 
cross sectional area by atherosclerotic plaque reduces the normal 
ability of the coronary vascular bed to reduce its resistance during 
maximal exercise resulting in ischaemia. A luminal reduction of ≥ 50% 
may be associated with ischaemia because coronary blood flow 
becomes inadequate to meet demand during exercise or stress.3 In 
addition, stenosis resistance changes relatively little with mild degrees 
of vascular narrowing but rises precipitously with severe obstruction 
such that resistance almost triples between stenosis of 80 and 90%. The 
ischaemic threshold is also influenced by other factors including the 
development of collateral circulation, the degree of transmural 
distribution of myocardial perfusion from the more vulnerable 
subendocardium to the subepicardium, coronary vascular tone and 
platelet aggregation.  
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Atherosclerosis is a chronic disease characterised by two fundamental 
hallmarks: lipid accumulation and inflammation. It is a progressive 
disease in which lipids, extracellular matrix and activated vascular 
smooth muscle cells accumulate in the arterial wall resulting in growth 
of atherosclerotic plaque.  After the formation of fatty streaks, the 
atheroma typically evolves into a more fibrotic and complex lesion 
which eventually leads to the clinical manifestation of CAD. Endothelial 
dysfunction is also considered an important prognostic factor indeed a 
precursor to the development of atherosclerosis. 10 
The mechanisms responsible for the sensation of angina are complex 
and not fully understood. Ischaemia does not always manifest as pain 
and can be silent with painless ischaemia described in all coronary 
syndromes including stable angina, unstable angina, vasospastic angina 
and myocardial infarction.3, 11 In addition the development of ECG  
changes may precede or follow the development of symptoms.11  
Myocardial ischaemia reduces the formation of adenosine triphosphate 
(ATP) resulting in the development of acidosis, the loss of the normal 
ATP-sodium potassium pump, the loss of myocardial membrane 
integrity and the release of chemical substances that stimulate 
chemosensitive and mechanoreceptive receptors innervated by the 
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unmyelinated nerve cells found within cardiac muscle fibres and around 
the coronary vessel. The substances released include lactate, serotonin, 
bradykinin, histamine, reactive oxygen species and adenosine. 8, 12 In 
addition there are substances released from platelets which often 
spontaneously aggregate in the area of coronary artery stenosis which 
may also be responsible for myocardial ischaemia and angina. These 
include serotonin, thromboxane A2 and 5 hydroxytriptamine.8 13 
There is substantial evidence the primary mediator of angina pain is 
adenosine via stimulation of A1 adenosine receptors.8, 11, 14 It is also 
possible that venodilation, as a response to ischaemia, can active these 
receptors. The nerve fibres travel along the sympathetic afferent 
pathways from the heart and enter the sympathetic ganglia in lower 
cervical and upper thoracic spinal cord. Impulses are then transmitted 
via the ascending spinothoracic pathways to the medial and lateral 
thalamus and ultimately active several areas of the cerebral cortex 
resulting in the sensation of angina. 
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1.2 Acute coronary syndromes 
Acute coronary syndromes (ACS) encompass a spectrum of disease 
from unstable angina to transmural myocardial infarction.  All have the 
common aetiology in the formation of thrombus on an inflamed and 
complicated atheromatous plaque due to plaque erosion and rupture.   
The definition of ACS requires a triad of clinical presentation, ECG 
changes and biochemical cardiac markers.  An ACS may occur in the 
absence of ECG changes or elevations in biochemical markers when the 
diagnosis is supported by presence of prior documented CAD or 
subsequent confirmatory investigations. 15 
 
1.2.1 Treatment of ACS 
Immediate treatment is defined by the characteristics of the presenting 
ECG, in particular the presence of ST elevation. In combination with 
clinical presentation, ST elevation of ≥ 2mm in at least 2 adjacent 
precordial leads,  ≥ 1mm in at least 2 adjacent limbs leads or the 
development of new left bundle branch block (LBBB) defines an ST 
elevation myocardial infarction (STEMI) and this is treated with 
emergency reperfusion. In the absence of ST elevation i.e. non ST 
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elevation ACS (NSTEMI) patients are initially managed without 
emergency reperfusion. 
Unstable angina is differentiated from NSTEMI by the serum 
concentration of cardiac markers. The cardiac markers troponin I and 
troponin T are highly sensitive to myocardial damage. The European 
Society of Cardiology (ECS) and American College of Cardiology (ACC) 
state that any elevation of troponin or creatinine kinase MB (muscle, 
brain) should be classified as a myocardial infarction.  The British 
Cardiac Society (BCS) and World Health Organisation (WHO) state those 
with no cardiac enzyme release should be classified as unstable angina, 
those with a minor troponin as ACS with myocyte necrosis and those 
with significant release as ACS with myocardial infarction.   
First line treatment essential for all patients presenting with ACS should 
include aspirin and synthetic pentasaccharides (e.g. fondaparinex) or 
low molecular weight heparin. Subsequently patients should be 
commenced on beta blocker, ACE inhibitor and statin.  
1.2.2 Pathophysiology of ACS 
The pathophysiology of ACS is due to a fissure, erosion or rupture of an 
atherosclerotic coronary plaque. The loss of integrity of the protective 
covering over an atherosclerotic plaque exposes the highly 
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thrombogenic contents of the core of the plaque resulting in platelet 
aggregation leading to subtotal or total vessel occlusion. Activated 
platelets release a number of vasoconstrictors which may further 
impair coronary flow through the stimulation of vascular smooth 
muscle cells both locally and distally. The haemodynamic compromise  
of the atherosclerotic plaque prior to rupture may have been mild16 and 
plaques are lipid filled with foam cells. Activation of inflammatory cells 
within the atherosclerotic plaque appears to play an important role in 
the destabilisation process. This is covered in more detail later on.  
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1.3 Uric Acid  
1.3.1 Metabolism of Uric Acid 
Uric acid (UA) is the end of product of the metabolism of purine 
compounds, produced in the liver from the degradation of dietary and 
endogenously synthesised purine compounds. Purine mononucleotides, 
guanylic acid (GMP), inosinic acid (IMP) and adenylic acid (AMP) are 
broken down into purine bases, guanine and hypoxanthine. These are 
then metabolised to xanthine and subsequently uric acid by the action 
of xanthine oxidase (XO). (See figure 2 and 3) 
 
 
 
 
 
 
 
 
 
 
GMP     IMP Adenylate Deaminase  AMP 
  nucleotidases   
       Guanosine                  Inosine  Adenosine Deaminase      Adenosine 
 
Guanine            Hypoxanthine 
 
 
                                        
      Xanthine oxidase  
   Xanthine  Uric Acid 
                                                             O2, H2O                    H2O2             
O2, H2O 
H2O2 
Xanthine oxidase 
Figure 2 Metabolism of uric acid 
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Figure 3 Structure of uric acid17 
 
Xanthine oxidoreductase (XOR) exists as two interchangeable forms, XO 
and xanthine dehydrogenase (XD). The term XOR is used to describe 
both forms of the enzyme.  XOR is part of a group of enzymes known as 
the molybdenum iron-sulfur flavin hydroxylases. XOR is widely 
distributed throughout various organs including the liver, intestine, 
lung, kidney, heart, brain and plasma with the highest levels being 
found in the small intestine and the liver.18-20 In the myocardium, it is 
largely localized to the capillary endothelial cells, although the vascular 
 
34 
 
endothelium and less so the myocardial cells contain xanthine 
dehydrogenase.  
XD is converted to XO by limited proteinolysis or oxidation of about 
eight cysteine residues to cysteine. Both forms of XOR oxidise xanthines 
however XO directly reduces oxygen to superoxide. The superoxide 
anions then form hydrogen perioxide and hydroxyl radicals by 
interacting with hydrogen ions. These molecules are highly reactive and 
referred to as reactive oxygen species (ROS). 
Uric acid is primarily secreted by the kidneys where it is completely 
filtered at the glomerulus and reabsorbed in the proximal tubule. 
Elevated serum uric acid may be the result of overproduction but is 
usually due to reduced excretion21. 
1.3.2 Uric acid and cardiovascular risk 
Epidemiological links between elevated serum uric acid and increased 
cardiovascular risk has been recognised for many years. 22, 23 Many 
studies have suggested the serum uric acid is a risk factor for 
cardiovascular events24-27 There is clear evidence from several studies 
that elevated serum uric acid is a strong independent predictor of 
hypertension and this was confirmed by a recent meta-analysis.28 
However although this relationship would implicate uric acid as an 
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indirect risk factor for cardiovascular disease, the question remains as 
to whether uric acid is a causal CV risk or something which increases 
concurrently with other causal factors, causing the CV risk.  Many 
studies have suggested the former is the case……….24-26, 29, 30 whereas 
others suggest the latter. 31 32-36 
The National Health and Nutrition Examination Survey (NHANES) I  
Epidemiological Follow up Study24 looked at almost 6000 patients aged 
24-74 years with no previous myocardial infarction or stroke and the 
mean follow up was 16.4 years. Baseline serum uric acid (SUA) was 
available for each subject with the mean (SD) SUA 327 (86) µmol/l 
(range 42-744 µmol/l). Men had significantly higher SUA levels than 
women and black people significantly higher than white. Mean levels 
increased with age.  
Patients were analysed in 4 quartiles; 1 – SUA less than 321 µmol/l, 2- 
SUA 321-263 µmol/l, 3- SUA 364-416 µmol/l and 4- SUA higher than 416 
µmol/l . Those in the higher quartiles had increasing blood pressures, 
cholesterol levels and BMI. SUA levels were substantially higher in 
those reporting recent diuretic use or alcohol use. During the follow up 
period 1593 (26.9%) died with 731 (45.9%) of these deaths attributed 
to cardiovascular death. Compared with the lowest quartile, age and 
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race adjusted death rates were higher in quartile 4 for both men and 
women. This difference was significant in women.  
Further analysis, controlling for other recognised risk factors, found the 
risk of cardiovascular (CVD) death increased as SUA levels increased in 
all groups except men using diuretics. 
A further epidemiological study 25looked at serum uric acid in patients 
with proven CAD on angiography. Almost 9000 patients were included 
in the analysis with baseline SUA levels and SUA level at 6 months 
documented. Patients were subdivided into 4 quartiles, < 4.7mg/dl, 4.8-
5.7mg/dl, 5.8-6.7mg/dl and >6.8mg/dl and the incidence of all events 
and cardiovascular events were noted over a 3 year follow up period. 
The incidence of cardiovascular and cerebrovascular events and all-
cause mortality were higher in the highest quartile than the others.  
The Losartan Intervention for Endpoint reduction (LIFE)29 study 
demonstrated the superiority of a losartan based regime over an 
atenolol based regime for reduction of cardiovascular morbidity and 
mortality. Sub analysis was performed to assess effect of baseline SUA 
on cardiovascular endpoints using a COX regression model. As has been 
previously report, baseline SUA was higher in men. After adjusting for 
other risk factors the analysis found baseline SUA remained significantly 
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associated with increased risk in women only.  The distribution of 
patients on diuretics was equal in both groups. 
A further epidemiological study assessed role of SUA in predicting 
mortality in type 2 diabetics.26 2845 patients with diabetes were 
included and followed up for 4.7 ± 0.8years (Range 1-5 years). Baseline 
SUA levels were noted with hyperuricaemia documented as ≥ 416 
µmol/l in men and ≥ 386 µmol/l in women. During the follow up period 
329 (12.1%) participants died with 145 (44.1%) dying from 
cardiovascular causes. After adjusting for several baseline factors, an 
independent association was found between serum uric acid levels and 
CVD mortality. This was not true however for all-cause mortality.  
Another cohort study performed in Finland30 included 1423 men with 
no prior history of diabetes, CVD or cancer. The main outcome was 
death from cardiovascular disease, with the mean follow up 11.9 years. 
There were 157 deaths during follow up with 55 of these CVD deaths. 
CVD mortality was associated with increased baseline SUA. Extensive 
adjustment for variables did not attenuate this association.  
The Rotterdam study 37 was another large prospective, population 
based study which looked at 4385 patients aged over 55 with no prior 
history of stroke or coronary artery disease. Patients were divided into 
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4 quartiles based on their baseline SUA. The mean follow up was 8.4 
years. High SUA was associated with risk of CAD. After adjustment for 
potential confounding factors this only slightly attenuated the 
association. The associated was noted to be stronger in patients with 
no hypertension. Patients on SUA influencing medication at baseline 
were excluded from analysis. 
The Framingham Heart study 31however was a large prospective 
observational study which followed 6763 patients for a mean of 23 
years – the longest follow up period to date. The analysis was sex 
specific as men of all ages have a higher SUA than comparable women. 
Analysis of their data showed serum uric acid was not associated with 
increased risk for CHD, deaths from cardiovascular disease, or death 
from all causes. Of note, in the subgroup of patients on diuretics, 
baseline SUA was not associated with subsequent CAD, death from CVD 
or all-cause mortality. It has been noted the Framingham population 
was almost exclusively white whereas NHANES population was more 
heterogeneous.  
Similar results were achieved in the ARIC study 32another prospective 
population based study which followed a total of 13504 healthy middle 
aged patients for up to 8 years. Patients were divided into quartiles 
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based on their baseline SUA with quartiles divided as SUA <4.4mg/dl, 
4.5-5.2mg/dl, 5.3-6.2mg/dl and >6.3mg/dl in women and <5.7, 5.8-6.5,, 
6.6-7.5mg/dl and >7.6mg/dl in men. SUA levels were found to be 
directly associated with most risk factors for cardiovascular disease 
including hypertension, LDL cholesterol, triglycerides, body mass index 
and waist/hip ratio. After adjustment for other risk factors the 
relationship between SUA and SAD became non-significant. Excluding 
patients on diuretics and analysing the data resulted in conclusions 
identical to the original data. 
 
A further cohort study33 performed in 22696 men with abnormal 
cholesterol, blood pressure, fasting blood glucose or urinary protein on 
routine examination, followed the patients up for an average of 6.5 
years (SD 1.9 years). The patients were divided into 4 quartiles of 
baseline SUA. Higher SUA was associated with hypertension, high 
cholesterol and obesity. During the follow up period there were 1625 all 
cause deaths, 387 cancer deaths and 323 atherosclerotic CVD deaths. 
The baseline uric acid level was not associated with increased risk of 
death in any quartile. In those with diabetes, SUA was associated with 
 
40 
 
increased risk of death from all causes, even after adjustment of the 
covariates. 
 
The 1967-1973 Chicago Heart Association Dectection Project in 
Industry36 screened 39665 employees of which 24997 had complete 
baseline data.  The relationship between uric acid and 5-year mortality 
from all causes, from CVD and CAD, was analysed in patients free from 
CVD at baseline. Analysis of the 5 year mortality in white men age 45-
64, in highest uric acid group, found all-cause mortality was higher. CVD 
and CHD death rates were also higher in men in the highest uric acid 
groups, even when hypertensives on treatment were excluded although 
the tendency was less strong.  However when controlled for differences 
in other variables there was no significance between uric acid and CHD 
and CVD deaths. Analysis of 13 year mortality found there was no 
significant trend between baseline serum uric acid and CHD or CVD 
mortality. 
 
A small cross sectional study analysed admission SUA levels in 240 
patients undergoing coronary angiography. 35 There was no correlation 
between SUA and the extent of coronary artery disease (P>0.05). In 
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addition there was no significant difference between patients divided 
into CAD negative and CAD positive groups, with regards to uric acid 
level. Stepwise multivariant analysis using CAD as the dependent 
variable and factors of age, gender, BMI, smoking, blood pressure, LDL 
cholesterol, HDL cholesterol, triglycerides, total cholesterol and SUA 
levels as independent variables did not show any significant difference. 
(P>0.05) 
A summary of the studies reviewed is noted in Table 2.  
 
Study Conclusion 
NHANES I 
Follow up 
Study 1971-
199224 
SUA levels independently and significantly associated with risk 
of cardiovascular mortality. 
JCAD25 Elevated SUA is an independent predictor of cardiovascular 
events and all-cause mortality combined in patients with CAD. 
LIFE29 Baseline SUA remained significantly associated with increased 
risk of cardiovascular morbidity and mortality in women only.   
Zoppini et al26 Higher SUA associated with increased risk of CVD mortality in 
type 2 diabetics, independent of several potential cofounders. 
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Table 2 Summary of studies 
 
There is therefore some evidence that uric acid may be an independent 
risk factor for cardiovascular disease and certainly convincing evidence 
increasing uric acid levels are associated with increased prevalence of 
Niskanen et al30 SUA strong predictor of CVD mortality in healthy middle aged 
men, independent of other variables. 
Rotterdam37 SUA is a strong risk factor for MI and stroke. 
Framingham31 SUA does not have a causal role in the development of CAD, 
death from CVD or death from all causes. 
ARIC32 Findings not consistent with SUA being independent risk factor 
for CVD. 
Jee et al33 Uric acid is not an independent factor for death from cancer, 
atherosclerotic CVD or all causes. 
Persky  et al36 For men the associations between SUA and mortality appear 
to be secondary to associations with uric acid and other risk 
factors. 
Hashemi et al35 Uric acid is not significantly associated with coronary 
atherosclerosis. 
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other cardiovascular risk factors. At present however the evidence 
remains conflicting and it is clear a large randomised controlled trial 
would be required to help answer the question.  
1.3.3 Cellular Actions of Uric Acid 
Hyperuricaemia has been linked to multiple pro-atherogenic processes 
including increased oxidative stress,18, 38 vascular smooth muscle 
proliferation and plaque instability.4, 27 Elevated uric acid is also found 
to induce a pro-inflammatory state and this correlates with increase in 
inflammatory markers such as CRP.19, 21  
 The secretion of inflammatory mediators and the inhibition of 
endothelial nitric oxide (NO) have been found to cause endothelial 
dysfunction. 29, 39  NO, synthesised by endothelial cells, prevents 
leukocyte and platelet aggregation, smooth muscle, lipid oxidation and 
elicits potent vasodilatory properties activating smooth muscle cells 
guanylate cyclase.40 
NO inhibition may also contribute to the evolution of atherosclerosis39  
and it has been reported that atherosclerotic plaque contains a 
considerable amount of uric acid.25  
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Furthermore it has been suggested that elevated SUA levels are 
associated with increased platelet adhesiveness and this effect could 
potentiate thrombus formation in patients with acute coronary 
syndromes. 25, 29, 38 
Another role of uric acid is as a mediator for the development of other 
risk factors, particularly hypertension although the mechanism for this 
remains unclear. One potential mechanism is the stimulation of the 
renin angiotensin system.38  
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1.4 Oxidative stress  
As described in section 1.1.3, oxidant by-products, such as superoxide 
anion (O2-) and hydrogen peroxide (H2O2) are produced in the body as a 
consequence of normal aerobic metabolism. These ROS molecules are 
highly reactive with other biological molecules due to the presence of 
an unpaired electron.41 Under normal physiological conditions the 
production of oxygen free radicals and peroxides is balanced by an 
efficient system of antioxidants which are molecules capable of 
scavenging ROS, thereby preventing oxidative damage.   
In pathological states free radicals may be present in relative excess. 
These states may be due to endogenous sources or external stimuli 
such as toxins, ionising radiation and ultraviolet light. The shift of 
balance in favour of oxidation, termed oxidative stress may have 
detrimental effects on cellular and tissue function. Enhanced 
production of ROS is a major cause of endothelial dysfunction.18 Free 
oxygen radical formation and release are also exacerbated by the 
activated neutrophils that congregate within ischaemic areas.19 
Furthermore oxidative stress and inflammation are closely linked.42  
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However the role of oxidative stress has been a much debated  issue 
because attempts to reduce oxidative stress using antioxidant vitamins, 
such as in the Heart Failure Outcomes Prevention Evaluation (HOPE) 
study, have consistently failed to demonstrate a benefit.18  Therefore 
more recent research has concentrated on mechanisms to reduce the 
formation of ROS rather than a scavenging approach to already formed 
ROS. 
The two major ROS generating are the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and the xanthine oxidase 
systems. NAPDH oxidase catalyses the reduction of oxygen, through 
electron donation from either NADH or NADPH, to generate superoxide 
(O2-). This system is thought to be the predominant driver of O2- 
formation. The most potent inducer of NADPH system is angiotensin 
II,18 this effect can be reduced by the ACE inhibitors, angiotensin II 
receptor antagonists and direct renin inhibitors which are in frequent 
clinical use.  Uric acid activates NADPH oxidase and inhibits nitric 
oxide.19  
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1.5 Allopurinol 
1.5.1 Allopurinol and angina 
The Clinical Outcomes Utilizing Revascularisation and Aggressive Drug 
Utilisation (COURAGE) trial research group found patients with stable 
CAD still had prominent rates of residual symptoms and impaired 
quality of life even in patients who had received optimum treatment. It 
is worth noting overall survival in angina is not usually improved by 
treatments which improve symptoms, but rather by those which reduce 
plaque formation and instability. With the exception of beta blockers, 
angina treatments which reduce symptoms are completely different 
from those which prolong survival.  The former are nitrates, Ca 
antagonists etc while the latter are statins, aspirin and ACE inhibitors.  
Improving survival is thus achieved through various mechanisms 
including reduction of endothelial dysfunction – this is currently 
achieved with statins and ACE inhibition.43   
Allopurinol has been shown in previous work to prolong the time to 
chest pain and ST segment depression during exercise in chronic stable 
angina.44 ‘It is known that myocardial ischaemia alters the redox state 
of the mitochondrial respiratory chain and ultimately promotes cellular 
adenosine triphosphate degradation, which leads to xanthine 
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accumulation and the subsequent increase in the substrate for xanthine 
oxidase’.19  
One study found that patients on optimal standard therapy still 
exhibited marked oxidative stress and in this study XOR inhibition with 
allopurinol profoundly improved vascular tissue oxidative stress and 
vascular dysfunction in patients with coronary artery disease.43 
It has been shown that allopurinol not only reduces urate levels but it 
also reduces oxidative stress and a number of mechanisms have been 
proposed as to why it would be useful in patients with CAD. 
1.5.2 History and pharmacokinetics 
Allopurinol was developed as an inhibitor of the enzyme xanthine 
oxidase. Although it is widely used to treat the hyperuricaemia 
associated with gout, it was initially used to inhibit XO catabolised 
metabolism of mercaptopurine,17 thereby potentiating the action of 
this cytotoxic drug. 
Allopurinol is an analogue of hypoxanthine (see figure 4).  It is a weak 
acid with an acid dissociation constant (pKa) of 9.4 and is therefore 
essentially un-ionised at all physiological PH values.17 The active 
metabolite is oxypurinol (see figure 5).  
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Figure 4 Structure of Allopurinol 
 
 
Figure 5 Structure of Oxypurinol 
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Allopurinol is largely metabolised to oxypurinol in the liver and excreted 
via the kidneys. After intravenous administration 12% +/- 6% (mean +/-
SD) of the dose of allopurinol is excreted unchanged in the urine with 
76% +/- 8% excreted as oxypurinol.17 The half-life is 18-30 hours in 
patients with normal renal function.45   
The standard dose initially is 100mg daily which can be titrated up to a 
maximum dose of 400mg daily. In patients with hepatic impairment the 
dose should be reduced and in patients with renal impairment the 
maximum dose is 100mg daily.46  
Side effects include rash, gastro-intestinal disorders and rarely malaise, 
headache, vertigo, drowsiness, visual and taste disturbances, 
hypertension, alopecia, hepatotoxicity, paraesthesia and neuropathy, 
gynaecomastia and blood disorders. Allopurinol is also rarely associated 
with the development of Stevens-Johnson syndrome and toxic 
epidermal necrolysis.47  
The basic mechanism of action of allopurinol and oxypurinol is 
inhibition of XOR. Allopurinol is a competitive inhibitor of XO at low 
doses and a non-competitive inhibitor at high doses. Oxypurinol  is also 
a non-competitive inhibitor of XO.19 This leads to decreased plasma 
concentrations of urate and elevated levels of the precursors, 
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hypoxanthine and xanthine. Hypoxanthine is converted to inosine, 
inosine monophosphate and closely related purine ribotides, adenosine 
and guanosine monophosphates.  
1.5.3 Reduction of oxidative stress 
Reducing oxidative stress has been shown to decrease myocardial 
oxygen demand per unit of cardiac output in patients with heart 
failure.48 In experimental medicine it has been shown this is primarily 
due to the effect of xanthine oxidase inhibition on oxidative stress. In 
addition, two studies using the intra-arterial Vitamin C technique to 
assess vascular tissue OS, have shown clearly that allopurinol 
profoundly suppresses vascular tissue OS even in the presence of 
conventional optimal therapy. 49, 50 If allopurinol really does reduce XOR 
induced oxidative stress in human angina this effect may contribute to 
its anti-anginal pain effect. 43  A major caveat is that in large multicentre 
trials, antioxidant vitamins did not reduce CV events but this may well 
be because the doses needed to mop up OS effectively are much higher 
than can be given orally.  In any case, blocking the formation of OS may 
be a better strategy as it is thought that at least some of the benefit 
seen by the use of both statins and ACE inhibitors is due to their ability 
to prevent OS forming. 
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1.5.4 Mechanoenergetic uncoupling 
This is the term used to describe a decrease in the efficiency of 
contraction despite a constant oxygen cost of contraction. The 
mechanisms responsible for mechoenergic uncoupling are unknown 
although experimental medicine suggests ROS play a major role.51 In 
animal models of heart failure it has been shown that XO inhibition 
improves myocardial efficiency and enhances the myocardial response 
to dobutamine and exercise.51 A study by Ekelund et al52 in which 
intravenous allopurinol 200mg was given to dogs with pacing induced 
heart failure in addition to a control group, found in both groups 
allopurinol resulted in increased myocardial contractility while reducing 
cardiac energy requirements. These findings were enhanced in the 
heart failure group.  
In a small study53 of patients with dilated cardiomyopathy (n=9) 
myocardial oxygen consumption, peak rate of rise of left ventricular 
pressure, stroke work and efficiency were measured at baseline and 
after sequential infusions of intracoronary allopurinol. Allopurinol was 
found to significantly decrease myocardial oxygen consumption without 
a parallel decrease in efficiency, stroke work or change in ventricular 
load. These effects were apparent despite concomitant treatment with 
 
53 
 
standard heart failure therapy including ACE inhibitors and beta-
blockers. 
1.5.5 Improvement of endothelial function 
Enhanced production of ROS is a major cause of endothelial 
dysfunction18 and allopurinol has the potential to improve endothelial 
function due to a reduction of oxidative stress which would in turn 
cause a reduction in vascular nitric oxide inactivation. In all patient 
groups studied, allopurinol was found consistently to improve 
endothelial dysfunction.39, 43   This was shown to be due to reduced OS 
and not due to changes in uric acid.39 This effect was also seen on top of 
conventional optimal therapy with statins and ACE inhibitors etc.  This 
ability of allopurinol to improve endothelial dysfunction raises the 
possibility that it could be useful to prevent or slow the progression of 
atherosclerosis. Numerous clinical studies have shown XO inhibition 
improves endothelial function in patients with diabetes, CAD, smokers 
and chronic heart failure.18 39, 43     
1.5.6 Improvement in coronary blood flow 
Coronary endothelial dysfunction is associated with vasoconstriction 
rather than vasodilatation when acetylcholine (traditionally a 
vasodilator) is given.  This effect extends to the coronary 
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microcirculation, the vasoconstriction contributes to myocardial 
ischaemia and subsequent angina.19 A number of clinical studies have 
found inhibition of XO by allopurinol or oxypurinol improves endothelial 
dysfunction in the forearm in smokers, heart failure, diabetes mellitus 
and hypercholesterolemia. 54-56 
An open-labelled prospective non-randomised trial of patients with 
stable CAD, preserved left ventricular function and normal SUA levels, 
whom had no current allopurinol intake assessed the subject’s coronary 
vasoconstrictor response to acetylcholine and changes in coronary 
blood flow after intravenous administration of oxypurinol. In patients 
with preserved coronary endothelial function, oxypurinol had no effect 
on acetylcholine-dependent changes in the arterial minimal lumen 
diameter. However in patients who displayed endothelial dysfunction 
as measured by a coronary vasoconstrictive response to acetylcholine, 
the study found significant improvement in coronary blood flow after 
administration of oxypurinol. This study concluded that XO derived free 
radicals greatly debilitated the availability of coronary nitric oxide in 
CAD and that XO inhibition as a treatment should be further 
investigated. 40 
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1.5.7 Atherosclerosis and plaque stability 
As described in section 1.1.5, atherosclerosis is a chronic disease 
characterised by 2 fundamental hallmarks namely lipid accumulation 
and inflammation. The interaction between these 2 processes defines 
the principal pathogenesis and distinguishes atherosclerosis from other 
chronic inflammatory disorders. Atherosclerosis is a progressive process 
in which lipids, extracellular matrix and activated vascular smooth 
muscle cells (VSMCs) accumulate in the arterial wall resulting in growth 
of an atherosclerotic plaque. The atheroma typically evolves into a 
more fibrotic and complex lesion. 57 It is known that inflammation plays 
a key role in atherogenesis and furthermore inflammation can elicit 
ACS.58 Elevated uric acid can induce a pro-inflammatory state and this 
correlates with increase in inflammatory markers such as CRP.19 
Many factors have been described which contribute to plaque 
instability in atherosclerotic disease. One factor is dysregulated 
metabolism of the extracellular matrix, principally due to focal 
overexpression of matrix metalloproteinases (MMP’s) which may 
contribute to weakening of the atherosclerotic plaques. It appears the 
integrity of the fibrous cap depends on a dynamic balance between 
collagen synthesis and degradation.57, 59 Inflammatory cytokines 
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regulate the expression of genes that direct interstitial collagen 
synthesis and MMPs which initiate breakdown of collage. Activation of 
MMPs seems to involve both inflammatory cytokines and oxidative 
stress. 57, 59  
Disruption of this balance results in plaque rupture which underlies as 
many as ninety percent of acute myocardial infarctions. The areas of 
the plaques prone to rupture are the ‘shoulder areas’ which often 
contain macrophages.4 Colocalisation of macrophage foam cells and 
active forms of MMPs within these vulnerable regions is likely relevant 
for disruption of atherosclerotic plaques.  There is a strong connection 
between plaque vulnerability and the presence of macrophages4 
however the mechanism whereby macrophages influence MMP activity 
remains poorly defined.  One study found that macrophage foam cells, 
isolated from atheroma, steadily produced O2-, H2O2 and NO without 
additional exogenous stimulation. The reactive oxygens were shown to 
module some MMP activity4 and this may play an important part in 
modulation of MMP activity in atherosclerotic plaques.  
MMPs also promote platelet activation. (See figure 6) 
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Figure 6 Features of stable and unstable plaques57 
Allopurinol may have a beneficial role in establishing plaque stability by 
reducing the production of the reactive oxygen species which module 
MMP activity. Furthermore the ability of allopurinol to improve 
endothelial/vascular function and to profoundly reduce OS suggests a 
possible role for allopurinol to prevent or regress atherosclerosis, even 
in the presence of conventional optimal therapy (statins, ACE 
inhibitors).   
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1.5.8 Adenosine Triphosphate 
Adenosine Triphosphate (ATP) is required for normal cardiac contractile 
function and has several roles: 
 Fuel the ion pumps that directly remove calcium from the cytosol 
during diastole namely the sarcoplasmic reticular calcium-ATPase 
pump and the sarcolemmal calcium extrusion pump  
 Provide energy for the sarcolemmal sodium pump (Na-K-ATPase). 
An active sodium pump is critical for achieving myocyte 
relaxation because the intracellular sodium concentration 
regulates intracellular calcium levels via sarcolemmal sodium-
calcium exchange. 
 ATP influences myocardial relaxation directly at the level of the 
myofilaments by interacting with actomyosin to cause its 
dissociation to actin and myosin, a step critical to relaxation60  
XO plays a critical role in the terminal degradation of ATP. By blocking 
XO, allopurinol has the ability to prevent adenosine triphosphate 
degradation in ischaemic tissue.19 There is also the potential that 
clinical benefit might also ensue from increasing the concentration of 
the substrates of XO namely hypoxanthine and oxygen, both of which 
should be increased by allopurinol blocking XO. ATP is broken down to 
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hypoxanthine and in theory; increasing hypoxanthine might increase 
ATP and thus energy.  Indeed data do show that allopurinol does 
indeed increase ATP in the hypoxic rat heart (by 32%).61  A study by 
Hirsh et al62 randomised patients with non-ischaemic cardiomyopathy 
to receive allopurinol (300mg intravenously) or placebo infusion and 
the myocardial concentrations of ATP and creatinine phosphate and the 
rate of ATP synthesis through creatinine kinase were determined by 
magnetic resonance spectrometry. The study found allopurinol acutely 
improved the relative and absolute concentrations of myocardial high 
energy phosphates and ATP flux (see figure 6).  
 
Figure 7 The rate of ATP synthesis through cardiac CK (μmol/g/s) under baseline 
and allopurinol conditions (summary bars represent mean ± SD).59T 
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The mechanism may in fact be more complex than described above and 
partly due to the effect of allopurinol on OS because OS inhibits 
cytosolic creatinine kinase which normally re-synthesises ATP.  
Another substrate of XO which could be relevant is oxygen and it has 
been shown that allopurinol can improve myocardial oxygen 
consumption in heart failure.51, 52 The mechanism of such an effect 
remains unknown but an increase in oxygen and/or ATP or both could 
be contributing. 
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1.6 Allopurinol in ACS 
There is the suggestion that allopurinol may also have a role in acute 
coronary syndrome and this can be attributed to a number of 
mechanisms. OS increases after myocardial infarction and is thought to 
induce ventricular dilatation and dysfunction and impair endothelial 
function. 63  Therefore improvement in endothelial function by 
decreasing OS might improve coronary perfusion to downstream 
ischemic areas as well as reduce future atherosclerosis.  Secondly the 
ability of allopurinol to reduce OS also raises the possibility that it might 
prevent plaque rupture which would be relevant to all acute ischemic 
CV events.  Thirdly, more ATP and oxygen might prevent downstream 
ischemic cardiomyocytes from dying.  To date one small study confirms 
that allopurinol can indeed reduce both troponin release and cardiac 
events after a ST elevation myocardial infarction.64  
Another study found allopurinol treatment initiated immediately after 
coronary artery ligation in mice reduced cardiac remodelling, with a 
marked reduction in myocardial ROS production, suggesting XO 
inhibition might be beneficial in myocardial infarction65.  
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1.7 Isoprostanes 
While oxidative stress is now recognised to be a prominent feature of 
many diseases, definite evidence of this has often been lacking due to a 
shortcoming of methods available to assess oxidative stress in vivo in 
humans.  Several in vitro markers of oxidative stress are available but 
most are of limited value in vivo because they lack sensitivity or 
specificity or require invasive methods. 66  
It has been established measurement of F2-isoprostanes is a reliable 
method to assess oxidative stress status in vivo.66 These bioactive 
prostaglandin-like compounds are formed by free radical-catalyzed 
peroxidation of arachidonic acid and act as vasoconstrictors. Some 
studies have shown cyclooxygenase inhibitors increase the amount of 
isoprostanes and exacerbate the loss of cardiac function due to 
ischaemic-reperfusion injury.67 Data has shown that allopurinol has the 
ability to significantly reduce F2-isoprostane levels in patients with high 
baseline oxidative stress.19 There are several advantages to using 
isoprostanes as a measure of oxidative stress. They are chemically 
stable, formed in vivo, present in detectable amounts in normal tissue 
and biological fluids allowing definition of the normal range and are 
unaffected by the lipid content in the diet. One caveat is that F2-
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isoprostane formation is impaired at elevated oxygen tensions such as 
hyperoxia induced lung injury.  
  
 
64 
 
1.8 Oxidised Low Density Lipoprotein (LDL)  
Lipids, such as cholesterol and triglycerides are insoluble in plasma and 
are transported in lipoproteins to various tissues for energy utilisation, 
lipid deposition, steroid hormone production and bile acid formation. 
These lipoproteins are classified by their subclass size and 
concentrations. There are five major lipoproteins each of which has a 
different function. 
• Chylomicrons – very large particles which carry dietary lipids. 
• Very low density lipoproteins - carry endogenous triglycerides 
and cholesterol. 
• Intermediate density lipoprotein - carry cholesterol and 
triglycerides. 
• Low density lipoproteins – carry cholesterol 
• High density lipoproteins – carry cholesterol 
LDL particles contain a core of cholesterol esters, lesser amounts of 
triglycerides but are enriched by apolipoprotein B-100 which is the 
ligand for binding to the apo B/E receptor. LDL can be internalised by 
hepatic tissue for conversion to bile acids or by non-hepatic tissue for 
hormone production, cell membrane synthesis or stored in the 
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esterified form. The internalisation of LDL is regulated via negative 
feedback of the B/E receptor expression.  
Chemically modified LDL such as oxidised LDL bypasses this negative 
feedback and is avidly taken up by macrophages and some other tissues 
through unregulated scavenger receptors. The oxidation process 
modifies a lysine amino acid on the apolipoprotein B and this process 
can occur within endothelial cells, macrophages, smooth muscle cells 
and T lymphocytes. The oxidation of LDL results in the formation of 
isoprostanes.  
This pathway can result in excess accumulation of intracellular 
cholesterol and the formation of foam cells which contribute to the 
formation of atherosclerosis. Oxidised LDL can cause endothelial 
dysfunction, increased platelet aggregation and may have a role in 
plaque stability.68-70 
A strong association between oxidised LDL and CAD has been shown by 
several studies68, 71 with increasingly levels of oxidised LDL correlating 
with severity of CAD.72 This was true after correcting for other CVD risk 
factors. Furthermore Meisinger et al68 found in apparently healthy 
middle aged men, levels of oxidised LDL could predict those who would 
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subsequently develop an acute cardiac event even after adjustment for 
other major risk factors.  
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1.9 C - Reactive Protein (CRP) 
CRP is an acute phase protein demonstrated to be a reliable 
measurement of inflammation. With emerging evidence on the role of 
inflammation in atherosclerosis, some studies have suggested a role for 
CRP in the oxidation of LDL and there is also evidence CRP is released 
from atherosclerotic lesions.73 Furthermore CRP has a potential role as 
a marker of cardiovascular disease and has been found to give a 
predictive value beyond that of traditional risk factors in patients with 
CAD even after adjustment for conventional cardiovascular risk 
factors.74-76   
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1.10 B-type Natriuretic Peptide (BNP) 
BNP is a 32-amino acid polypeptide which is released into the 
circulation from the myocardial membrane in response to myocardial 
stretching and increased left ventricular end diastolic pressure. BNP has 
an established role in the diagnosis and prognosis of left ventricular 
heart failure. Furthermore elevated BNP levels after acute myocardial 
infarction have a strong prognostic value.77  
More recently it has been shown elevated levels of BNP at rest were 
independently associated with inducible ischaemia during ETT or stress 
echocardiography. The half-life of BNP is 20 minutes which means it 
may be possible to detect short term changes induced by exercise and 
indeed exercise induced ischaemia. A study by Win et al77 found in 
subjects without heart failure, undergoing ETT, the BNP levels increased 
significantly post exercise and decreased towards baseline with 10-
15minutes post exercise. This was true for patients with and without 
ischaemia but more pronounced in those with ischaemia.  
A further study by Staub et al also found BNP levels increased 
significantly during acute myocardial ischaemia induced by dynamic 
exercise. This rise was not noted in angiographically normal subjects.78 
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A study by Paraskevaidis et al,79 measured serial BNPs while exercising 
patients with preserved left ventricular function who were referred to 
outpatient clinic with chest pain. These patients then underwent 
coronary angiography. This study found BNP values were consistently 
increased in both the CAD and non-CAD groups (as determined 
angiographically) with the changes in the CAD group more pronounced. 
These findings were similar to those noted by Win et al. The study also 
found the degree of change was higher in patients with more severe 
CAD (see figure 7). Interestingly a further study by Davidson et al 80  
found that although disease of left anterior descending artery were 
associated with increasing BNP levels as previously noted, the BNP 
levels were independently reduced by disease of the right coronary 
artery. They concluded this paradoxical effect of right coronary artery 
disease limited the value of BNP measurements as predictors of 
coronary disease severity.  
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Table 3 Serial BNPs and severity of CAD 
 
It has been suggested therefore that in patients with stable CAD, 
resting BNP values are associated with the presence of myocardial 
ischaemia and angiographic disease severity. Moreover it has been 
consistently shown BNP values are powerful predictors of death in 
patients with stable CAD or ACS.   
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1.11 Troponin T 
The myocardial sarcomere consists of 7 actin monomers, double 
stranded tropomyosin and a troponin complex. The troponin complex is 
composed of 3 subunits – troponin T which anchors the complex to the 
tropomyosin strand, troponin C which binds calcium ions released from 
the sarcoplasmic reticulum and troponin I which inhibits the enzyme 
hydrolyses of ATP. Troponin is released from the myocardium in 
response to ischaemia. Troponin levels have an established role in the 
assessment of patients presenting with acute coronary syndrome as it is 
a specific marker of myocyte necrosis. 
Troponin release has also been noted after exercise and a meta-analysis 
of 26 studies looking at athletes found post exercise troponin 
concentrations were detectable in approximately half the 
participants.81 More recent studies found in an non-athletic population 
troponin was released after prolonged walking and the magnitude of 
the release was related to exercise intensity and cardiovascular 
pathology.81   
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1.12 ETT 
ETT is the most widely used test in the evaluation of patients presenting 
with suspected CAD. It is well validated for establishing diagnosis and 
prognosis of CAD, as well as assessing exercise capacity. The sensitivity 
and specificity of ETT have been derived from studies correlating the 
ECG response to exercise with coronary angiographic data. Patient 
gender, age, coronary risk factors and the characteristics of the chest 
pain are also important determinants of the pre-test probability of 
coronary heart disease and therefore the diagnostic accuracy of ETT. 82 
Sensitivity in men is 0.68 while in women it is 0.61, specificity is 0.77 in 
men and 0.70 in women.6   The Duke score was developed to predict 
prognosis. (see figure 8)  
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Figure 8 Duke Score and Outcome 
 ST depression during exercise is one the main ECG change used to 
assess ischaemia. The test is considered positive when there is ≥1mm 
horizontal or down-sloping ST depression in one or more leads that 
persists at 80milliseconds after the J point. (see figure 9 and 10) 
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Figure 9 Example of J point 
 
 
Figure 10 Example of ST depression 
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Indications for ETT  
ETT can be used to assess patients with: 
• Symptoms suggesting myocardial ischaemia 
• Acute chest pain in who ACS and MI have been excluded 
• Recent ACS treated without angiography 
• Prior coronary revascularisation 
• Valvular heart disease 
• Newly diagnosed heart failure or cardiomyopathy 
• Certain cardiac arrhythmias 
Contraindications for ETT 
• Acute myocardial infarction 
• Unstable angina 
• Uncontrolled arrhythmia causing symptoms of haemodynamic 
compromise 
• Symptomatic severe valvular stenosis 
• Uncontrolled symptomatic heart failure 
• Active endocarditis 
• Acute aortic dissection 
• Acute pulmonary emboli 
 
76 
 
There are 2 main groups of patients in whom ETT is limited. 
Firstly, in those who due to a physical limitation, are unable to 
exercise sufficiently. Secondly patients with ECG changes at rest 
which can interfere with the diagnosis of ischaemia.  
 
There are a number of reasons an ETT may be stopped. Firstly 
patient determined reason such as the patient wishes to stop, 
has significant chest pain, marked fatigue or shortness of breath 
or any other limiting factors. Secondly the supervising doctor 
may stop the test if the patient looks unwell, develops exertional 
hypotension, exertional hypertension (systolic BP >200, diastolic 
BP >100). Thirdly several ECG endpoints would require the test to 
be stopped including marked ST depression, new bundle branch 
block, new high grade heart block, ventricular tachycardia or 
fibrillation, increasing ventricular ectopy and onset of 
supraventricular tachyarrhythmia. Finally the test end may be 
protocol determined ie target heart rate achieved or workload 
determined. 
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1.13 Summary  
This three arm cross over, double blind trial was designed with aim of 
assessing the role of allopurinol on patients with ischaemic heart 
disease, in particular to establish time of onset of effect of the drug and 
the optimal dose.  George et al 39 demonstrated that a steep dose–
response relationship existed between allopurinol and its effect on 
endothelial function. If the onset of allopurinol was found to be rapid it 
may be required to be started quickly in patient with ACS to obtain 
maximum benefit.  Patients with chronic stable angina were used as 
surrogate of the acute coronary syndrome, since they are easier to 
study as a group, to answer key questions of the speed on onset of 
allopurinol and the optimal dose. This would then inform potential 
study of allopurinol in ACS patients.  
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2 Methods 
2.1 Overview 
This study was a randomised double-blind, placebo-controlled, three 
arm cross over trial, run in accordance with the Declaration of Helsinki 
and The Medicines for Human Use (Clincal Trials) (Amendment) 
Regulations 2006. 
The aim of the study was to determine whether allopurinol prolonged 
the time to ST depression on exercise treadmill test in patients with 
chronic stable angina and if so to establish how quickly this effect was 
noted and the optimum dose to achieve this.  
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2.2 Approvals 
Sponsor Approval  
Reference 2010CV30  
Submitted 30th August 2011 
Sponsorship was confirmed and permission to apply for CTA granted on 
the 7th October 2011. 
 
Ethical Approval 
Reference 11/ES/0033 
Submitted 11th October 2011   
An favourable reply was received from East of Scotland Research Ethics 
Service REC 2 on 11th November 2011 provided further information was 
submitted. A letter providing this was submitted on 15th November 
2011 and a final approval received 22nd November 2011. 
 
NHS R&D Approval 
Reference  2010CV30 
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Submitted 18th October 2011 
Approval was granted 12 January 2012 
 
MHRA Approval 
Reference  21726/0277/001/0001 
Submitted 24th November 2011 
The application was accepted on 23rd December 2011. 
Trial Registries 
ClinicalTrials.gov: the study was registered and allocated reference 
NCT01457820 
EudraCT: the study was registered and allocated reference 2011-
004966-35 
 
Funding 
Reference  PG/11/14/28774 
An application for funding was submitted to the British Heart 
Foundation on 25th October 2010. This was considered at the Projects 
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Grants Committee and an award covering the full costs was awarded on 
31st March 2011.  
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2.3 Study Protocol 
Individuals aged 18 to 85 years were recruited from outpatients at two 
Tayside Hospitals (Ninewells Hospital and Perth Royal Infirmary) and via 
the SPCRN.   
 
2.3.1 Inclusion Criteria 
Participants were recruited if they fulfilled the following inclusion 
criteria 
• Aged 18 – 85 years 
• A positive ETT – this was defined as development of ST 
depression ≥ 1mm at 80ms after the J point compared to 
baseline in at least one lead. 
• A history of symptoms of chronic, stable, effort-induced angina 
for ≥ 2 months – patients with unstable angina or rest pain were 
excluded as they would be high risk for the repeated ETTs 
required in this study. 
 
All concomitant antianginal medication were allowed and continued 
unchanged during the study.  
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2.3.2 Exclusion Criteria 
• the inability to do an ETT due to back or leg problems  
• myocardial infarction or acute coronary syndrome ≤ 2 months – 
these patients may be unstable and will be undergoing 
optimisation of standard therapy during this time. 
• coronary revascularization (percutaneous or CABG) ≤ 6 months – 
patients take up to six months to fully recover from bypass 
surgery and the risk of in-stent stenosis after percutaneous 
intervention is highest in the early months following the 
procedure. 
•  Left ventricular ejection fraction <45% - repeated ETT’s in 
patients with heart failure carry a higher risk. 
• estimated GFR <60 ml/min or creatinine >180 mmol/ml – as 
allopurinol is renally excreted impaired renal function may lead 
to an increased frequency of side effects. 
• significant valvular pathology – patients with valve disease are at 
higher risk during ETT. 
• already had gout or on allopurinol – this would make findings 
difficult to interpret. 
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• atrial arrhythmias or ECG abnormalities interfering with ST-
segment interpretation – as these would make the ETT difficult 
to report.  
• previous ventricular arrhythmias on ETT – as these would make 
the patient high risk for repeated ETT. 
• severe hepatic disease – allopurinol is contraindicated in these 
patients.  
• on azathioprine, 6 mercaptopurine or warfarin – as these drugs 
interact with allopurinol. 
• Patients who have participated in any other clinical trial within 
the previous 30 days will be excluded 
• Patients who are unable to give informed consent will also be 
excluded from this trial 
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2.4 Cohort size and power calculation 
Power calculations were carried out by a statistician, Dr Simon Ogston, 
using the real data from our previous study of allopurinol in chronic 
stable angina. 83  In that study, where n=60, the standard error (SE) of 
the estimated effect on ST depression during exercise was 6.75s 
(derived from 58-31/4).  Therefore, the standard deviation of 
differences was 52.3s (derived from SE x √60).  This meant in a target 
number of 60 individuals, we would have 80% power to detect a 
different effect size between the different doses of 18.9 secs (derived 
from (1.96 + 0.84) x 52.3/√60).  A difference of 18.9 seconds at peak 
drug effect between different doses of allopurinol would represent an 
8% change over the patients’ baseline time to ST depression (232 
seconds) in our previous study. 83  A number of 60 subjects would make 
our study appropriately sensitive to detect clinically significant 
differences between the various doses of allopurinol. Allowing for a 
10% drop out rate we intended to recruit 66 participants. 
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2.5 Recruitment 
Recruitment proved to be highly challenging in this study. A number of 
methods were used to identify potential participants. 
 
2.5.1 The Scottish Primary Care Research Network (SPCRN) 
Participants were recruited using the East of Scotland node of the 
SPCRN. This network was established in 2002 to help coordinate 
national research activity in primary care. It is funded by the Chief 
Scientists Office, centrally managed by the Scottish School of Primary 
Care and operationally managed at a regional level in Scotland. 
 
The co-ordinator for the East of Scotland contacted GP practices within 
the network by post to invite them to be involved in the study. 
Practices willing to be involved were visited by a SPCRN research officer 
who screened their patient database electronically using the patient 
eligibility criteria to generate a list of potential participants. This list was 
then screened by a GP in the practice to exclude patients who may have 
reason not to be invited.  
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A letter of invitation (see Appendix A) was then posted out to the final 
list of potential participants on the practice headed paper along with a 
copy of the patient information sheet (PIS) (see Appendix B), a reply slip 
(see Appendix C) and a stamped addressed envelope.  Individuals 
interested were invited to reply by post or by telephone to FS. Patients 
were then contacted via telephone and an appointment booked for 
screening. A confirmation of appointment was sent by letter where 
necessary (see appendix D) 
 
2.5.2 Cardiology Outpatients 
At the beginning of the study, general cardiology outpatient clinics in 
Ninewells were screened to identify suitable patients but it became 
clear patients attending general outpatient cardiology clinics did not fit 
the criteria.  Details of all patients attending the rapid access chest pain 
clinic who were found to have a positive exercise tolerance test were 
forwarded to FS by the secretary for this clinic. 
 
2.5.3 Angiography Database 
A list of patients attending for angiograms over a six month period was 
generated by the radiology department in Ninewells. This list was then 
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further screened using the clinical portal on the NHS system by a 
research nurse. Patients found to be for medical management or with 
residual disease were identified and letters of invitation were sent 
containing PIS and reply slip as above to these individuals.  
 
2.5.4 Informed Consent 
All patients had received the PIS at least 24 hours in advance of 
attending for their screening visit. The programme of the study was 
outlined and all had the opportunity to ask questions prior to signing a 
written consent form (see Appendix E).  
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2.6 Study Visits 
All study visits were carried out at the Department of Clinical 
Pharmacology, Ninewells Hospital, Dundee or the outpatient cardiology 
department, Perth Royal Infirmary.  
 
Following written informed consent, the screening visit was completed. 
This involved an initial clinical assessment comprising 
 
• Check of inclusion/exclusion criteria 
• Past medical history 
• Family history 
• Social history  
• Examination 
• Height 
• Weight 
• Resting pulse and blood pressure 
• Record of concomitant medications 
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Patients also had baseline safety bloods drawn. 
 
A baseline ETT was then performed. Participants had to demonstrate 
ischaemia defined as ST depression of ≥1mm ST depression compared 
to their baseline ECG. Participants who did not demonstrate ischaemia 
were excluded from the study. 
 
Participants who demonstrated ischaemia underwent a second ETT 
within 2 weeks of the first ETT. Eligible participants had to demonstrate 
ischaemia on both visits with a variability in time to ST depression of 
<15%.  Otherwise a third ETT was performed (within 14 days of the 
second ETT) and the above criterion of time to ST depression was 
applied between the second and the third ETT.  
 
This ETT criterion was set to exclude patients with a wide variation in 
the time to ST depression on repeated ETTs. Similar criterion has been 
used in other trials assessing anti-anginal agents.84-86 
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Participants then proceeded to the first randomisation visit. Another 
baseline ETT was performed one hour before the participant was dosed 
with either allopurinol 800mg or allopurinol 400mg or matched 
placebo. An ETT was performed 4 hours after the loading dose 
administration. Participants were then given a sealed bottle and asked 
to take one tablet twice a day for 5 days thereafter. The medication for 
this 5 day period was either allopurinol 400mg BD if started on 800mg 
loading dose, or 300mg BD if started on the 400mg loading dose, or 
matched placebo BD. Compliance was checked and documented using 
tablet counts at each visit.   
The patient then returned the following day for another ETT and again 
4 days +/- 1day for a further ETT. A washout period of a minimum of 
seven days occurred before the patient entered the second then third 
arm of the trial. Each arm was identical in format apart from the dose 
of allopurinol/placebo.  
 
A full visit schedule is provided in table 4. 
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• Visit 1 (week 0) – screening visit 1 
o Participant consent – answer any outstanding questions and 
complete consent form. 
o Baseline ETT 
o Safety bloods 
o Record list of current medications 
o Record of medical history & CAD history 
 
• Visit 2 (week 1) – screening visit 2 
o Second baseline ETT – if stable (<15% variance) then can 
continue in study 
o Record list of current medications 
 
• 1-4 week screening to randomisation period 
 
• Visit 3  – Randomisation visit (Day 0) 
o ETT one hour before study drug dosing 
o Dosing with Allopurinol/Placebo 
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o 2nd ETT after 4 hours of study drug dosing 
o Record list of current medications 
o Supply of full dose study medication x 5 days 
o Safety and research bloods. 
o Issue angina diary to participants 
 
• Visit 4 progress visit  (Day 1) 
o ETT 
o Monitor AEs 
o Safety and research bloods  
o Review angina symptom diary 
 
• Visit 5 – progress visit (Day 5 +/- 1 day) 
o Assess medication compliance. 
o ETT 
o Check for AEs 
o Safety and research bloods. 
o Review angina symptom diary 
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• 1-4 week washout period 
 
• Visit 6   - Randomisation visit (Day 0) 
o ETT one hour before study drug dosing 
o Dosing with Allopurinol/Placebo 
o 2nd ETT within 4 hours of study drug dosing 
o Record list of current medications 
o Supply of full dose study medication x 5 days 
o Issue angina diary to participants 
o Safety and research bloods. 
o Check for AEs 
 
 
• Visit 7  – progress visit (Day 1) 
o Assess medication compliance. 
o ETT 
o Check for AEs 
 
95 
 
o Safety and research bloods. 
o Review angina symptom diary 
 
• Visit 8  – progress visit (Day 5 +/- 1 day) 
o Assess medication compliance. 
o ETT 
o Check for AEs 
o Safety and research bloods. 
o Review angina symptom diary 
 
• 1-4 week washout period 
 
• Visit 9 Randomisation visit (Day 0) 
o ETT one hour before study drug dosing 
o Dosing with Allopurinol/Placebo 
o 2nd ETT within 4 hours of study drug dosing 
o Record list of current medications 
o Supply of full dose study medication x 5 days 
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o Issue angina diary to participants 
o Safety and research bloods. 
o Check for AEs 
 
• Visit 10  – progress visit (Day 1 day) 
o Assess medication compliance. 
o ETT 
o Check for AEs 
o Safety and research bloods. 
o Review angina symptom diary 
 
• Visit 11 – final visit (Day 5 +/-1 day) 
o ETT 
o Assess medication compliance. 
o Safety and research bloods. 
o Check for AEs 
o Record list of current medications 
Table 4 Visit schedule  
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2.7 Randomisation 
Double blind medication (allopurinol or placebo) was prepared and 
packaged by Tayside Pharmaceuticals.  The medication was labelled in 
sequential numbers and distributed to the participant by the research 
fellow according to their sequence number.  Randomisation was carried 
out by Tayside Pharmaceuticals using block randomisation in eleven 
groups of six (with three active/three placebo in each block).  A 
validated randomisation program was used and securely backed up 
containing both the randomisation seed and the randomisation 
allocation.  The randomisation key was held in sealed enveloped by 
Tayside Pharmaceuticals, Ninewells, who operate a 24 hour emergency 
unblinding facility.  An additional copy was stored in a locked fireproof 
box accessible by authorised University of Dundee staff not connected 
with the study. 
At the time of patient proceeding to randomisation a letter was sent to 
the participant’s GP (See appendix F) and a copy filed in their medical 
notes along with a copy of their signed consent form and contact 
details for the PI. 
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2.8 Outcome measurements 
2.8.1 Primary and secondary outcomes 
The primary outcome was to determine if allopurinol, of different 
doses, induced a change in time to exercise induced ST depression in 
patients with CSA when compared to placebo and, if so, when that 
effect comes on. 
Secondary outcomes were: 
• To determine if there was a change in total exercise time on ETT, 
at different doses of allopurinol in CSA patients compared with 
placebo. 
• To determine if there was a difference in time to CSA patients 
reported symptoms of chest pain during exercise testing with 
different doses of allopurinol compared with placebo. 
• To determine if there were changes in blood markers, specifically 
BNP, high sensitivity Troponin T and hsCRP, during exercise 
testing in patients with CSA at different doses of allopurinol 
compared with placebo. 
• To assess, using self-reporting diaries, if there were differences in 
CSA patient’s symptoms of angina pain and GTN usage when 
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treated with different doses of allopurinol compared with 
placebo.  
  
2.8.2 Exercise tolerance test 
These were conducted using the Bruce protocol (see table 2) which is 
the most widely used protocol in the assessment of patient with 
suspected or documented coronary artery disease. The protocol is 
divided into successive three minute stages each of which requires the 
patient to walk faster and at a steeper gradient.  
Stage Grade (%) Speed 
(mph) 
Total Time 
(min) 
METS 
1 10 1.7 3 4.5 
2 12 2.5 6 7 
3 14 3.4 9 10 
4 16 4.2 12 13 
Table 5 Bruce Protocol for ETT 
The machine used was a GE Marquette Series 2000 Treadmill Stress 
Testing System (GE Healthcare Clinical Systems (UK) Ltd, Hatfield, UK). 
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The tests were conducted in accordance with the University of Dundee 
SOP for ETTs and supervised by FS (PI, Cardiology Registrar and 
Advanced Life Support Instructor) and a trained nurse. Patients had 
blood pressure checked at baseline, every three minutes throughout 
the ETT and repeated during the recovery period to ensure it was 
settling back to baseline. ECG monitoring was continuous throughout 
the test and during the recovery phase until the ECG returned to 
baseline and blood pressure was satisfactory. Full resuscitation 
equipment was available at all times. 12-lead ECGs were printed at 30 
second intervals and more frequently at the point of 1mm ST 
depression. 
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2.8.3 Angina Diary 
Patients were issued with an angina diary (see Appendix F) and asked to 
complete this throughout the study period. They were reminded at all 
visits to complete the diary. The aim of the diary was to document if the 
frequency of the angina attacks varied on different arms of the trial. 
The diary included a section for the date, number of attacks on a given 
day, the trigger for the attack, the severity of attack which was rated 1-
4 (1-mild, 2-somewhat strong, 3- severe, 4-very severe),  the duration 
of the attack and the intervention required to resolve the angina.  
2.8.4 Laboratory tests 
Safety Bloods – Full blood count, urea & electrolytes and liver function 
tests 
A total of ~ 9 ml of venous blood was drawn at the patients initial visit 
with 5 ml serum for biochemistry and 4ml EDTA for haematology. These 
tubes were labelled using the ICE requesting system and hand delivered 
to the NHS blood sciences lab on level 7, Ninewells where automated 
analysis was carried out to NHS Tayside standards.  
Patients randomised into the trial had these safety bloods taken and 
analysed at every visit. Any abnormal result was acted upon within 24 
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hours of the sample being drawn and the results were documented in 
the CRF. 
The hard paper copy was annotated with the patient ID number and 
the name and hospital identification number were blacked out. All 
paper copies were stored with the CRF. 
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Test Normal reference range 
Haemoglobin 13.0-18.0 g/dL (men), 12.0-16.0 g/dL 
(women) 
White cell count 4.0-11.0 x109/L 
Platelets 150-400 x 109/L 
Sodium 133-146 mmol/L 
Potassium 3.5-5.3 mmol/L 
Urea 2.5-7.8mmol/L 
Creatinine 62-106 µmol/L 
Alanine Transaminase (ALT) 5-35 U/L 
Alkaline Phosphatase (Alk Phos) 30-130U/L 
Bilirubin 0-21 µmol/L 
Albumin 35-50 g/L 
Table 6 Reference Ranges for Safety Bloods 
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Study Bloods - Uric Acid, Troponin T, CRP, Oxidised LDL and 
Isoprostanes.  
Patients randomised had study bloods taken at every visit.   
At all visits, baseline bloods were drawn of ~ 25ml of venous blood 
which was split into 2 x 10ml ETDA tubes and 5ml serum tube. (These 
samples were drawn at the same time as the safety bloods). The study 
tubes were stored on ice then centrifuged for 10 minutes at 3000rpm at 
4ºC. The EDTA plasma was extracted and put into microtubes 
individually labelled for isoprostanes and oxidised LDL. These samples 
were the stored at -70 ºC. The serum was extracted and put into 
microtubes individually labelled for CRP, Troponin T and uric acid. 
These were stored at -20 ºC.  
At visits 3, 6 & 9 a further ~5ml serum sample was drawn 2 hours after 
the loading of the study drug. This sample was handled in the same way 
as the serum sample above and stored for uric acid.  
A ~25ml sample was then drawn before and after the second ETT of 
visits 3, 6 & 9 and these samples were handed as the baseline bloods. 
For visits 4, 5, 7, 8, 10 & 11 the baseline sample was taken as described 
above and a second ~25ml sample of venous blood was drawn 
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immediately after the ETT on these visits. These bloods were also 
handled in the same way as the baseline samples described about. 
All bloods were analysed blindly by the Immunoassay Core Lab, 
Cardiovascular and Diabetes medicine, University of Dundee, Ninewells 
Hospital.  
Study Bloods - BNP  
BNP was analysed by FS or the study nurse using the bedside Biosite 
Triage Meter. Alere BNP testing kits were stored in the cold room and 
removed 15 minutes prior to use as per the SOP. A 1ml of blood was 
removed from the EDTA tubes used for oxidised LDL and isoprostanes 
prior to these being centrifuged. This blood was pipetted onto the 
testing kit and the analysis ran. The machine gave a print out of the 
result which was dated and recorded in the paper CRF. If a sample was 
not available this was recorded and a sample of plasma from the 
corresponding visit was analysed by the Immunoassay Core Lab. BNP 
was analysed at all points oxidised LDL and isoprostanes was as 
recorded above.  
 
106 
 
2.9 Data entry and managment 
 Data from all study visits were recorded in the paper clinical record 
form (CRF) (see Appendix G) by either FS or the nurses working in the 
trial and recorded on the delegation log. All ETT print outs were signed, 
dated and numbers and stored along with the CRF in locked cabinets in 
the PI’s office. The anonymised bloods results and completed angina 
logs were stored along with the ETTs and CRFs.  
Electronic storage of the data was on the Openclinica system. There 
were significant delays in this being available and therefore the 
majority of the data were entered retrospectively. Data was double-
data entered by FS and the study nurse. Data entry was double checked 
by an independent person with no links to the trials who ensured all 
data entered was consistent with data in CRFs. 
2.10 Statistical analysis 
The statistical analysis plan was drawn up by Daniel Levin, university of 
Dundee statistician. The main analysis was on an intention-to-treat 
basis.  
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2.11 Adverse Events 
Participants were asked about adverse events at every visit and any 
adverse event was documented in the paper CRF. Any serious adverse 
event (SAE) or serious adverse reaction (SER) was reported to the 
sponsor in accordance with The Medicines for Human Use (clinical 
trials) Amendment Regulations 2006.  
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3 Results 
3.1 Recruitment 
As noted in section 2.5.1, the majority of patients were identified via 
the SPCRN network with a small number from out-patient clinic and the 
angiography database.  Patients identified by the SPCRN network were 
further screened via GP databases by SPCRN staff to ensure eligibility 
before invitation letters were sent out. Patients identified from 
cardiology outpatients and the angiography data base were further 
screened via NHS Tayside clinical portal before invitations were sent 
out.  
22 practices were screened by SPCRN with a total of 2492 invites send 
to patients. 122 patients accepted via this process, with 38 patients 
declining the invitation.  
Patients replied by posting back reply slips in prepaid envelopes or by 
telephoning the department. They were called by the PI and further 
screened over the telephone before being invited for face to face 
screening.  
A total of 121 patients were screened with 26 (21%) proceeding to 
randomisation. The high failure rate in passing screening was largely 
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due to insufficient ECG changes on the ETT with 57 (60%) patients not 
having sufficient changes to meet study criteria. A further 3 patients 
(3%) found it too difficult to walk on the treadmill, 3 (3%) developed 
severe hypertension on the ETT, 1 patient was excluded as their renal 
function was below the threshold for inclusion, 1 patient withdrew 
from screening as they had a chest infection and a final patient was 
excluded as there was a finding of a new murmur on the initial clinical 
examination.  
The recruitment period was extended, as recruitment was challenging, 
for a further six month period. In addition we gained approval to extend 
the trial into NHS Fife, increasing the pool of patients.  
The first screening visit occurred  9th May 2012 with the final visit 7th 
November 2014. 
Five patients did not complete the study post randomisation. One 
patient injured his knee and was unable to continue on the treadmill, 
one patient felt the intensity of the study was too much for him and 
withdrew after the second arm, another withdrew as she did not like 
the frequency of the blood tests, a fourth patient withdrew on the last 
visit as he has developed a rash and a final patient was removed from 
the trial following a SUSAR. 
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Due to the complexity of the data collected in this study the statistical 
analysis was performed by statistican Daniel Levin. 
 
3.2 Baseline Characteristics 
Variable Number % 
Gender (Male) 20 77 
Cardiology exam abnormal 2 8 
Respiratory exam 
abnormal 
0 0 
Abdominal exam abnormal 0 0 
Neurology exam abnormal 0 0 
Family history coronary 
disease (Yes) 
15 58 
Father (Yes) 8 31 
Mother (Yes) 7 27 
Brother (Yes) 6 23 
Sister (Yes) 4 15 
Previous smoker 14 54 
Retired  22 85 
Living Alone  3 11.5 
Angina 26 100 
MI 9 35 
Stroke 1 4 
Hypertension 9 35 
Hypercholesteraemia 11 42 
Table 7 Patient characteristics 
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Table 8 Patient characteristics 
 
Variable Number 
missing 
Mean SD Median Min Max 
Age 0 70.1 6.2 69.5 61 83 
Height 0 1.69 0.07 1.68 1.51 1.81 
Weight 0 81.6 14.0 81.4 55.3 117.6 
BMI 0 28.6 4.2 28.4 22.4 40.7 
Pulse 0 70 12.9 69 51 93 
Systolic 0 135.7 20.1 140 98 168 
Diastolic 0 76.5 11.0 79 60 100 
BNP (Predose, visit 3) 0 51 43 33 2.5 140 
HB g/dL (visit 3) 2 14 1.4 13.85 11.7 16.5 
WCC x109/L (visit 3) 2 6.7 1.8 6.35 4 10.3 
PLTS   x109/L (visit 3) 2 224 49.5 218 138 376 
Na mmol/L (visit 3) 0 140 1.8 140.5 136 144 
K mmol/L (visit 3) 0 4.3 0.32 4.3 3.5 5 
Urea mmol/L (visit 3) 0 6.2 1.4 5.9 3.3 8.6 
Creat µmol/L (visit 3) 0 77 12.5 75.5 55 110 
ALT 5 U/L (visit 3) 1 27 11.4 25 11 63 
Bilirubin µmol/L (visit 
3) 
1 9 3.4 8 2.5 15 
Alk Phosphatase U/L 
(visit 3) 
1 77 18 77 38 114 
Albumin g/L (visit 3) 1 38 2.6 39 32 41 
Uric acid 0 424.6 143.7 403.1 217.6 898.7 
Of 14 ex-smokers: 
  Cigarettes Per day  
 
0 
 
33.8 
 
17.3 
 
35 
 
10 
 
60 
  Yrs smoked 0 23.2 10.8 25 5 48 
  Yrs stopped 1 18.8 12.6 24 2 45 
Yrs since diagnosis: 
Angina (25 pts) 
 
5 
 
13.2 
 
8.1 
 
11.5 
 
2 
 
32 
MI (9 pts) 2 16.3 12.2 12 5 40 
Stroke (1 pt) 0 17 - 17 17 17 
Hypertension (9 pts) 8 16 - 16 16 16 
Hypercholesteraemia 
(11 pts) 
11 - - - - - 
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Table 9 shows the number of patients on cardiac medications. 
Medication Number of Patients   Percentage 
Beta-blocker 21 81 
Ace-inhibitor 14 54 
Angiotension inhibitior 3 12 
Calcium  channel 
blocker 
9 35 
Statin 23 88 
Nitrate 14 54 
Aspirin 23 88 
Diabetic medication 4 15 
Table 9 Patient Medications 
 
Angiography results were available for 20 subjects. Table 9 shows the 
distribution of coronary artery disease in these subjects. LMS is the left 
main stem, LAD is left anterior descending artery, LCx is the left 
cicumflex and RCA is the right coronary artery. 
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 No 
disease 
Plaque 
disease 
25-50% 
stenosis 
50-74% 
stenosis 
74-94% 
stenosis 
>95% 
stenosis 
LMS 16 2 2 0 0 0 
LAD 4 5 1 1 3 6 
LCx 7 5 1 3 1 3 
RCA 5 2 4 2 5 2 
Table 10 Table of distribution of coronary artery disease 
 
The number of patients with significant (>50% stenosis) single, double 
or triple vessel disease is detailed in table 10. 
Vessels with 
>50% stenosis 
0 1 2 3 
Number 6 6 4 4 
Table 11 Number of vessels involved 
 
Five patients had undergone coronary artery bypass grafting and eight 
had a history of percutaneous coronary intervention.   
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3.3 Adherence to medication 
Patients were asked to bring their medication with them to visits and 
these were counted to ensure compliance. The tablet count indicated 
patients were 100% compliant. Furthermore uric acid levels were 
checked at every visit and, as shown in figures 11-13, the uric acid 
dropped significantly in both treatment arms of the trial but not in the 
placebo arm which is consistent with compliance.  
 
 
Figure 11 Uric acid levels low dose 
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Figure 12 Uric acid levels at high dose 
 
Figure 13 Uric acid levels placebo 
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A a
 
 
Figure 14 median uric acid per treatment arm 
 
Treatment A is low dose allopurinol, B high dose allopurinol and C 
placebo.  The median plots also show that patients were compliant with 
their medications. 
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3.4 Adverse Events 
One patient had a serious adverse event when he became very unwell 
an hour after the loading dose in the second arm. He had an episode of 
collapse with loss of consciousness and hypotension but no ECG 
changes, followed by a second collapse episode. He was admitted to 
hospital for an overnight stay and all investigations were normal. The 
cause for his collapse episodes were not clear. This was reported and 
fully investigated by the monitoring committee. The patient was 
withdrawn from the study. 
Another patient developed a rash during the wash out period between 
the second and third arm, thought to be unrelated to the study. 
  
 
118 
 
3.5 Exercise treadmill test 
The exercise treadmill results were independently validated by a 
blinded reviewer and were consistent in 98%. Discrepancies were 
reviewed and final data agreed.  
The output from Open Clinica provided the time to ST depression, the 
total exercise time and the time to chest pain for each ETT for each 
subject. For each of the time to ST depression and total exercise time, a 
linear mixed model was fitted using the SAS 9.3 PROC MIXED 
procedure, including the baseline measurement, treatment (A, B, C), 
period (1,2,3), measurement replication number (1,2,3) and a period-
by-treatment term and with a compound symmetry correlation 
structure between repeated measures between person and treatment. 
87 This type of analysis was recommended by the statistician for the 
trial.  
3.5.1 Time to ST depression (st1mm)   
The figure below shows the mean time to ST depression for each 
treatment arm. A is low dose allopurinol, B is high dose allopurinol and 
C is placebo. This shows that the time to ST depression was higher in 
the allopurinol arms although this was not significant.  
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A low dose, B high dose, C placebo 
Figure 15 Mean time to ST depression for each arm 
 
Spaghetti plots were then done for each subject in each arm of the trial 
to look for obvious outliers. 
Figures 16-18 show these: 
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Figure 16 Time to ST depression low dose allopurinol 
 
Figure 17 Time to ST depression high dose allopurinol 
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Figure 18 Time to ST depression placebo 
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The median difference was also plotted as shown in figure:
 A low dose, B high dose, C placebo 
Figure 19 Median change in time to ST depression 
 
The baseline (pre-dose) measurement had the biggest effect on post 
dose measurement (P<0.0001) but no significant overall treatment 
effect on time to ST depression (P=0.78)  
Overall there was no treatment difference on time to ST depression.  
• A - B:  difference (95% CI) = -6.4 (-25.2,12.4), p=0.49 
• A - C: difference (95% CI) = -4.7 (-23.9, 14.5), p=0.62     
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• B - C: difference (95% CI) =  1.7 (-17.1, 20.6), p=0.85 
A is low dose, B is high dose and C is placebo. 
The P values and the fact the confidence intervals cross 0 both 
confirm there was no significant effect. 
3.5.2 Total exercise time 
The figure below shows the mean total exercise time for each 
treatment arm. A is low dose allopurinol, B is high dose allopurinol and 
C is placebo. This shows that the total exercise time was higher in the 
allopurinol arms at 24 hours.  
 A low dose, B high dose, C placebo 
Figure 20 Mean total exercise time by treatment and time from baseline 
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There was significant overall treatment effect on total exercise time 
(P=0.024) 
This showed up in the effect of treatment differences, with a significant 
effect of both treatments A & C compared to B on total Exercise time.  
• A - B:  difference (95% CI) = -18.0 (-33.9,-2.0), p=0.028 
• A - C: difference (95% CI) = 3.1 (-13.4, 19.5), p=0.71     
• B - C: difference (95% CI) = 21.0 (4.8, 37.3), p=0.012 
 
This shows that high dose (B) was more effective than low dose 
(A) and placebo (C). Low dose (A) was also more effective than 
placebo (C) although this difference was not significant as P=0.71 
and the confidence intervals cross 0.  
 
The Figures below show the spaghetti plots for each subject in 
each arm of the trial. 
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Figure 21 Total exercise time low dose allopurinol 
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Figure 22 Total exercise time high dose allopurinol 
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Figure 23 Total exercise time placebo 
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Each subject’s exercise time progression throughout the trial was then 
plotted. (Figure 24) 
 
Figure 24 total exercise time for each subject across study 
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It was felt there was general trend to increase in total exercise time 
from start to finish so this was analysed further by looking at the total 
exercise time changes in each arm compared to the baseline exercise 
time.  
The figures below show the range of total exercise time at baseline and 
final ETT for each arm, with the third box plot showing the difference in 
time from baseline to final ETT. The figures represent the placebo arm, 
the low dose arm and the high dose arm consecutively. 
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Figure 25 Boxplots of total exercise time placebo arm 
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Figure 26 Box plots of total exercise time low dose arm 
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Figure 27 Boxplots of total exercise time high dose arm 
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The numbers are detailed in the table below.  
  Placebo (c) High-dose (b) Low-Dose (a) 
Global 
Baseline 
Min 109 109 109 
Q1 266 266 266 
Q2 367 393 389 
Q3 551 551 551 
Max 734 734 734 
Mean (sd) 411 (174) 415 (173) 413 (170) 
Final 
visit 
within 
arm 
Min 186 215 207 
Q1 295 290 299 
Q2 378.5 385 416.5 
Q3 572 602 583 
Max 781 719 722 
Mean (sd) 448 (183) 450 (161) 444 (164) 
Final - 
BL 
Min -137 -113 -199 
Q1 -11 -15 1 
Q2 32.5 30 53.5 
Q3 83 68 79 
Max 180 275 171 
Mean (sd) 34 (68) 35 (80)                45 (73) 
 t-test (final - BL) 
t=4.12, 
p=0.00011 t=3.8, p=0.00031 t=5.04, p<1e-05 
 Wilcox test (final – BL) 
V=1746, 
p=0.000043 
V=2082, 
p=0.00053 
V=1758, p<1e-
06 
 
Table 12 Total exercise time changes over global baseline by arm 
The global baseline is the total exercise time at the first visit of each 
arm, the final exercise time is the total exercise time on the final ETT at 
the end of each arm and the difference between these times is shown 
at the bottom. Q2 represents the median value. The paired t-test  uses 
the individual paired (baseline and final) values to see if the mean of 
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 baseline and mean of final values were different and found there was a 
significance difference in each arm. To allow for the possibility of the 
data not being normal distributed wilcox tests performed using the 
median valves.  
  
3.5.3 Time to chest pain during exercise 
As the patients did not regularly get chest pain on the treadmill there 
was not a reliable amount of data to analyse from this perspective.  In 
total nine patients reported pain at baseline during the study in one or 
more of the arms with reporting pain during the high dose arm, seven 
during the low dose arm and eight reporting chest pain during the 
placebo arm.  
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3.6 Blood tests 
3.6.1 Troponin 
Troponins were not detected in any of the patients throughout this 
study. 
3.6.2 Oxidised LDL 
Figure shows the median oxidised LDL for each arm of the trial and visit. 
Treatment A is half dose, B full dose and C placebo. Visit 0 refers to the 
baseline blood sample before the trial drug was given, visit 1 refers to 
the post ETT bloods taken at the 4 hour ETT, visit 2 refers to the post 
ETT bloods at 24 hours and visit 3 to the post ETT bloods taken on the 
final visit of the arm.  
 A low dose, B high dose, C placebo 
Figure 28 Median Oxidised LDL for each treatment arm 
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Figures 30-32 show the oxidised LDL level for each subject in each arm 
of the trial. 
 
 
Figure 29 Oxidised LDL per subject placebo 
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Figure 30 Oxidised LDL per subject low dose allopurinol 
 
 
Figure 31 Oxidised LDL per subject high dose allopurinol 
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3.6.3 CRP 
Figure 32 shows the median CRP for each arm of the trial and each visit. 
Treatment A is low dose, treatment B is high dose and C is placebo. Visit 
0 refers to the baseline blood sample before the trial drug was given, 
visit 1 refers to the post ETT bloods taken at the 4 hour ETT, visit 2 
refers to the post ETT bloods at 24 hours and visit 3 to the post ETT 
bloods taken on the final visit of the arm. 
 A low dose, B high dose, C placebo 
Figure 32 Median CRP for each treatment arm 
Figures 33-35 show the CRP for each subject in each arm of the trial.  
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Figure 33 CRP per subject placebo 
 
 
Figure 34 CRP per subject low dose allopurinol 
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Figure 35 CRP per subject high dose allopurinol 
 
3.6.4 BNP 
Figure 36 shows the median BNP for each arm of the trial and each visit. 
Treatment A is low dose, treatment B is high dose and C is placebo. Visit 
0 refers to the baseline blood sample before the trial drug was given, 
visit 1 refers to the post ETT bloods taken at the 4 hour ETT, visit 2 
refers to the post ETT bloods at 24 hours and visit 3 to the post ETT 
bloods taken on the final visit of the arm. 
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 A low dose, B high dose, C placebo 
Figure 36 Median BNP per arm 
 
Figures 37-39 show the BNP for each subject in each arm. 
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Figure 37 BNP per subject placebo 
 
 
Figure 38 BNP per subject low dose allopurinol 
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Figure 39 BNP per subject high dose allopurinol 
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3.7 Angina Diary 
The return of diaries was insufficient to allow any meaningful analysis. 
This was due to the poor completion of the diaries and infrequency of 
chest pain experienced by patients. Since each treatment phase lasted 
such a short time it was never anticipated that the diary data would be 
meaningful. 
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4 Discussion 
This double-blind, placebo controlled, three arm cross over trial aimed 
to determine the time of onset and the optimal dose of allopurinol in 
patients with coronary artery disease using patients with stable disease 
as a surrogate for acute coronary syndromes. In this section the 
findings of the study (already presented in the results section) will be 
discussed and the possible underlying mechanisms for these findings, 
along with the strengths and limitations of this study, will be 
considered. 
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4.1 Recruitment 
Recruitment for this study proved to be extremely challenging. This was 
in essence due to a local change in clinical practice.  Patients had 
previously undergone diagnostic angiograms in Tayside and were 
referred across to Edinburgh Royal Infirmary if they required 
intervention. This meant patients with coronary artery disease could be 
identified and recruited to participate in clinical trials while they 
awaited being listed for interventional procedures. Now patients 
undergo one procedure whereby coronary artery disease is identified 
and treated during the same procedure.  
Significant effort went into recruiting patients and many avenues were 
explored in an effort to identify patients. This included extending to 
using the Perth Royal Infirmary exercise treadmill, extending to Fife to 
recruit more patients and exploring extending to Grampian.  
This study also required a significant commitment from patients who 
had to be available three days within one week and furthermore had to 
be able to repeat this commitment twice to complete the study. There 
was also a high intensity of exercise with four treadmills within one 
week which demanded a degree of fitness from the patients. Despite a 
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high number of patients being invited to participate in the trial the 
uptake was low. Furthermore the changes in clinical practice, which 
means symptomatic patients are stented much earlier, meant that 
many patients did not have ongoing ischaemia required to produce ST 
changes on treadmill test.  
The challenges of recruitment within this study are a cautionary tale 
which highlight the importance of resilience in trial design to adapt to 
the often rapid changes in clinical practice.  
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4.2 Primary Outcome – Time to ST depression on ETT 
The results of the primary outcome are laid out in section 3.5.1.  It can 
be seen that the mean time to ST depression was shorter in all arms of 
the trial on the ETT four hours post loading. This may be because this 
was the second ETT of the day for the patients or it may indicate 
allopurinol does not work within this short time frame. Interestingly by 
24 hours post loading, for both the low dose and high dose arms of the 
trial there was an increase in the time to ST depression. This was not 
sustained by day 5 in either active arms of the trial. Furthermore in the 
placebo arm of the trial the total time to ST depression showed a 
gradual increase over the arm. None of these changes in time to ST 
depression shows statistical significance but this may be due to the fact 
the study was underpowered due to small number of participants. It is 
also worth noting the median uric acid levels did not fall until the third 
visit of each arm which would suggest the biological effects are mainly 
after the study period ends. This may explain why the previously noted 
effects of allopurinol on time to ST depression are not shown in this 
study.44 It is also possible the drug effects on tissue oxidative stress 
described in the introduction, are exerted before the drug reduces the 
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urate level which is why the time to ST depression initially increased 
although it is difficult to explain why this effect would then be lost.  
Interestingly if we look at the spaghetti plots for each individual subject 
there are some outliers for whom the time to ST depression does 
increase in each of the active arms of the trial but not in the placebo 
arm. 
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4.3 Secondary Outcomes 
4.3.1 Total exercise time 
It was also interesting to note that as per the primary outcome, at 24 
hours there appears to be improvement in the mean exercise time in 
both treatment arms which is not fully sustained on day 5. In addition 
the placebo arm shows a progressive increase in total exercise time 
across the arm and the final total exercise time for all three arms are 
very similar. In the high dose arm the total exercise time fell four hours 
after the loading dose, but increased slightly in the low dose and the 
placebo arm. In view of the delay in fall of uric acid noted above it is 
difficult to explain these observations. Was the improvement noted at 
24 hours simply chance? This seems unlikely based on the previous 
work by Noman et al.44 However, as the sub-analysis of the total 
exercise time revealed, there was a significant improvement in all arms 
of the trial in terms of total exercise time which may reflect a degree of 
conditioning. This may suggest the five day negative effect was due to a 
the training effect overwhelming any drug effect.   The effects of high 
intensity training in cardiovascular disease is discussed below.  
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4.3.2  Time to chest pain 
As patients did not reliably experience chest pain during ETT there was 
insufficient data to draw any conclusions. Patients also did not 
complete their chest pain diaries. However the infrequency of chest 
pain experienced, again reflects the changes in clinical practice in that 
patients with ongoing chest pain undergo coronary intervention to 
alleviate their symptoms if these are not controlled medically. NICE 
guidelines 88 state that if patients symptoms are not controlled with 
two anti-anginal drugs, they should only be put on a third while 
awaiting intervention. 
4.3.3  Bloods 
Troponin 
As noted in the results chapter, troponin was not detected in any of the 
blood samples collected. This is not unexpected as the subjects were 
stable and did not have acute coronary events during the study.  
Neither did the patients have heart failure or renal impairment which 
have had associated troponin release, as these were exclusion criteria 
for the study.  
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Oxidised LDL 
Interestingly the median oxidised LDL was noted to fall 4 hours after 
the administration of the study drug in both the active and placebo arm 
and the fall was greatest in the high dose arm. The oxidised LDL levels 
then rose at 24 hours, rising most in the active arms, which was when 
the time to ST depression and total exercise time improved most. This 
again is difficult to rationalise as the time to ST depression fell at four 
hours after the study drug was administered. As noted in section 1.8, 
increasing levels of oxidised LDL correlated with severity of CAD so the 
fact the levels fell at the point where ischaemia is demonstrated more 
quickly is an unusual finding. Oxidised LDL is however a fairly inexact 
and insensitive test of tissue oxidative stress and therefore we should 
not assume too much from these findings.  
CRP  
There was no clear trend in the CRP across the arms of the study. 
BNP 
Interestingly in the treatment arms of the study the BNP did show a 
trend towards a lower reading in the later visits of the active arms 
compared with the placebo arm.  The median BNP rose slightly at 4 
hours in all three arms which was when the time to ST depression was 
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shorter in the active arms, then fell at 24 hours and further on the final 
visit. This is interesting because as described in the introduction, 
section 1.10, elevated levels of BNP are associated with inducible 
ischaemia. However, it would have been expected BNP would fall at 24 
hours when the time to ST was longest in the treatment arms and then 
come back closer to baseline as the time to ST depression shortened 
again. One explanation is that allopurinol exerted an anti-ischaemic 
effect by the end of the arm resulting in the BNP levels going down.  
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4.4 ETT as outcome measure 
Exercise treadmill tests have been used for more than six decades to 
detect CAD.89, 90 Current guidelines advise categorizing patients as low, 
intermediate or high risk. High risk patients are then advised to undergo 
coronary angiography, intermediate risk patients to undergo a stress 
test such as myocardial perfusion scan or stress echo while low risk 
patients should not be investigated further.7 Despite this, ETT remains a 
widely used approach being used routinely in 59% of chest pain clinics 
in the UK 91 and was part of the initial assessment of 76% of patients 
with chest pain in a Euro heart survey. 92 One study found that 
evaluation of individuals without known CAD, who presented with 
stable chest pain, using ETT as first line and further tests only if ETT 
equivocal, was a cost effective approach.93  An ETT gives additional 
information on exercise capacity, cardiorespiratory fitness and 
prognosis. For example, the Duke Treadmill Score, which was initially 
used as a prognostic score, has been tested as diagnostic score and was 
found to predict coronary arterial disease more accurately than ST 
response alone. 94  
Several factors can affect the specificity of ETT, resulting in false 
positive results, including metabolic conditions, structural heart 
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conditions and some medications.95 Furthermore the pattern of 
underlying CAD affects the specificity and sensitivity of the test. It is 
reported in patients who subsequently underwent coronary 
angiography, the sensitivity of ETT was approximately 68% and 
specificity 77%.95 This paper also reported the sensitivity for patients 
with single vessel disease varied from 25% to 71% and was most 
sensitive in patients with a lesion of left anterior descending artery. In 
patients with multi-vessel CAD, the sensitivity was reported as 86% and 
specificity 66%. In addition, ETT is less accurate in women due to an 
increased number of false positives. 96  
A key question is whether time to ST depression on ETT is really the 
best endpoint for clinical trials such as these. As the high failure rate in 
the initial screening visits show, the changes in clinical practice make 
finding patients with predictable ST depression on ETT incredibly 
challenging. It may be that using total exercise time as an alternative 
outcome would allow continued use of ETT findings as an outcome 
measure.  
There are several alternative methods to assess for coronary arterial 
disease causing cardiac ischaemia which include single-photon emission 
computed tomography (SPECT), stress echo, cardiac magnetic 
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resonance imaging, coronary CT angiography and fractional flow 
reserve derived from coronary CT angiography. A meta-analysis 
comparing these modalities 97 found cardiac MRI performed well in 
diagnosing haemodynamically significant coronary arterial disease on 
both a per-patient as well as per-vessel basis.  Cardiac CT and fractional 
flow reserve CT had a high diagnostic sensitivity, with a low specificity 
for cardiac CT. The diagnostic performance for the other modalities lists 
above was generally found to be poorer.  
Other studies have shown promising findings for the use of cardiac MRI 
perfusion scanning to assess for myocardial ischaemia and suggest this 
modality could be used as a first- line imaging modality for the 
exclusion of haemodynamic relevant coronary artery stenosis in 
patients with suspected coronary artery disease (CAD). 98 This modality 
can also give information on the haemodynamic relevance of coronary 
stenosis and guide subsequent revascularisation. However MRI is 
expensive, time consuming and requires the patients to comply. Using 
this as a repeated test to look for impact on inducible ischaemia would 
not be practical.  
Cardiac CT and SPECT both involve exposure to radiation and therefore 
again are not appropriate methods of repeat assessment at short 
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intervals due to cumulative toxic effects of radiation exposure. This is 
also true for myocardial perfusion scans.  
Stress echo is easily accessible but requires the patient to have good 
echo windows and the person reporting the scan to be highly skilled in 
order to pick up subtle changes in left ventricular wall motion. It can be 
seen therefore that all the current modalities to assess for inducible 
ischaemia have benefits and limitations.  
Alternatively should we consider giving up methods of assessing 
ischaemia in these patients and rely on angina diaries. The low return of 
completed diaries suggest compliance with this approach can also be a 
challenge. 
Overall ETT remains a reasonable test to assess for ischaemia in chest 
pain and for the purpose of this study was an easy, accessible method 
of evaluating the effects of allopurinol on the primary and secondary 
ETT outcomes. Certainly ETT parameters have been the cornerstone of 
clinical trials to assess the more recent anti-anginal medications to be 
marketed. 84, 99-101 
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4.5 High intensity exercise training 
Several of the study participants reported they found the ETT easier to 
do as the trial progressed and this is reflected in the significant 
improvement in mean total exercise time across all the arms of the trial 
from baseline ETT to final ETT irrespective of whether it was an active 
or placebo arm.  One participant felt so much improved by the end of 
the trial she actually went out and bought a treadmill for the house 
while a second joined the local gym so he could continue to exercise. 
The study involved the participants doing from 3-10 mins of quite 
intensive exertion three times per week, which was essentially a form 
of high intensity training (HIT). HIT has been the subject of research in 
many conditions over recent years including cardiovascular disease.  
Cardiac rehabilitation in the form of exercise is a well-established 
intervention to improved quality of life and survival in coronary artery 
disease.102-105 However the most efficient modality and intensity 
remains unclear. Some studies suggest HIT improves cardiovascular 
fitness and quality of life104 106although a recent meta-analysis 
concluded there was insufficient evidence at present.102  
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As noted in the introduction (1.1.5) endothelial dysfunction is believed 
to play a role in the development of atherosclerosis. Therefore 
interventions that prevent or slow endothelial dysfunction are 
important in reducing cardiovascular risk. 10 It has been shown exercise 
training in older adults helps to preserve endothelial function. This 
adaptive response is explained by the sheer stress induced during 
elevated blood flow results in vascular adaptation.10 It has also been 
shown that in patients with CAD, a reversal of the pathological 
remodelling and systolic and diastolic improvements were observed 
only after high-intensity exercise training.105 
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4.6 Challenges 
As discussed in section 4.1, recruitment was by far the most challenging 
aspect of this study. Despite extensive efforts to maximise recruitment 
the study remained under-recruited. This was largely due to the change 
in clinical practice as described previously. Interestingly, despite the 
visit schedule being quite demanding, most patients did complete the 
study unless they had to withdraw for health reasons. Furthermore a 
couple of subjects were quite disappointed when the study concluded 
as they enjoyed interacting with the team. 
 
In addition analysis of the findings of this study were difficult to 
interpretation due to variability in the sample in terms of current drug 
therapy, baseline fitness frequency of angina. Furthermore attempting 
to answer two questions in terms of optimal dose and timing on onset 
of allopurinol  made the data more difficult to interpret.  
4.7 Learning points 
• Changes in local practice must be considered when considering 
recruitment for trials 
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• It may be better to run a pilot study to ascertain ease of 
recruitment prior to commencing large study 
• Attempting to answer more than one question as primary 
outcome makes analysing data more challenging. 
• Reduction of variability in sample would make data analysis 
easier.  
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4.8 Summary 
This study was underpowered and so it is difficult to draw significant 
conclusions but it does appear at 24 hours there was an impact on both 
time to ST depression and total exercise time which warrants further 
investigation. This was noted despite the fact the uric acid levels did not 
fall until the end of the treatment arms.  
Our protocol was unusual because we were trying to establish a 
parameter which is not usually considered, namely the time of onset of 
the anti-ischaemic effect.  
It was shown that regular high intensity exercise improved the total 
exercise time irrespective of whether the treatment arm was active or 
placebo. This may suggest the protocol was contaminated by the 
training effect of repeated high intensity exercise. As discussed above, 
other methods of establishing ischaemia have their limitations; for 
many, sequential assessment is prohibitive due to exposure to 
radiation.  
It seems to be clear that allopurinol does not exert an anti-ischaemic 
effect in the first four hours after administration. This means that even 
if it were to become an established treatment in acute coronary 
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syndromes in the future it would not need to be delivered very quickly. 
Furthermore it would be unlikely to be worth formulating allopurinol as 
a sublingual spray for the management of acute coronary syndromes or 
even to relieve chest pain during an acute episode of exercise induced 
angina.  
Further work is required to answer the questions asked by this study 
but trial design would have to be rethought to address the challenges 
of difficult recruitment and training effects which have been identified 
by this study.  
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5 Appendix 
A Letter of Invitation 
 
 
165 
 
B Patient Information Sheet 
 
 
166 
 
 
167 
 
 
168 
 
 
169 
 
 
170 
 
 
171 
 
 
172 
 
 
173 
 
 
174 
 
 
 
 
175 
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